John Bernard Buse - the UNC Department of Medicine
John Bernard Buse - the UNC Department of Medicine
John Bernard Buse - the UNC Department of Medicine
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
CURRICULUM VITAE<br />
Personal Information<br />
Name: <strong>John</strong> <strong>Bernard</strong> <strong>Buse</strong>, MD, PhD<br />
Office Address: University <strong>of</strong> North Carolina School <strong>of</strong> <strong>Medicine</strong><br />
Division <strong>of</strong> Endocrinology<br />
CB# 7172, 8027 Burnett Womack Bldg<br />
Chapel Hill, NC 27599-7172<br />
919-843-3289 (<strong>of</strong>fice, Jill) 919-216-2039 (pager)<br />
919-966-6025 (fax) 919-966-4131 (page operator)<br />
jbuse@med.unc.edu (e-mail) 919-923-6963 (cell)<br />
Clinic Address: <strong>UNC</strong> Highgate Specialty Centre<br />
5316 Highgate Drive, Suite 125<br />
Durham, North Carolina 27713<br />
919-484-1015 (clinic phone)<br />
919-806-2181 (clinic fax)<br />
Education/Certification<br />
2001-2011 Recertification in Endocrinology, Diabetes and Metabolism<br />
1998-2003 National Certification Board for Diabetes Educators<br />
1994- Physician and Surgeon, State <strong>of</strong> North Carolina (#94-00739)<br />
1991-2001 Sub-specialty Certificate in Endocrinology, Diabetes and Metabolism<br />
1989- American Board <strong>of</strong> Internal <strong>Medicine</strong>, Certificate #129712<br />
1988-2001 Fellow, Clinical Investigator Pathway, Section <strong>of</strong> Endocrinology, <strong>Department</strong><br />
<strong>of</strong> <strong>Medicine</strong>, University <strong>of</strong> Chicago<br />
1987-1988 Resident, Internal <strong>Medicine</strong>, University <strong>of</strong> Chicago<br />
1986-1987 Intern, Internal <strong>Medicine</strong>, University <strong>of</strong> Chicago, Chicago, IL<br />
1986-1996 Physician and Surgeon, State <strong>of</strong> Illinois (#036-077120)<br />
1986- Drug Enforcement Agency Registration (#BB1430432)<br />
1979-1986 M.D., Duke University, Durham, NC<br />
Ph.D., Physiology/Immunology, Duke University, Durham, NC<br />
1982-1985 Pre-Doctoral Fellow, Joslin Diabetes Center, Boston, MA<br />
1976-1979 A.B., cum laude, Dartmouth College, Hanover, NH, Biochemistry
<strong>Buse</strong>, Curriculum Vitae p. 2 <strong>of</strong> 29 Updated: August 2008<br />
Pr<strong>of</strong>essional Experience<br />
December, 2006 Pr<strong>of</strong>essor, Division <strong>of</strong> Endocrinology, <strong>Department</strong> <strong>of</strong> <strong>Medicine</strong>, University <strong>of</strong><br />
North Carolina School <strong>of</strong> <strong>Medicine</strong>, Chapel Hill, NC<br />
August, 1994 Associate Pr<strong>of</strong>essor, Division <strong>of</strong> Endocrinology, <strong>Department</strong> <strong>of</strong> <strong>Medicine</strong>,<br />
University <strong>of</strong> North Carolina School <strong>of</strong> <strong>Medicine</strong>, Chapel Hill, NC<br />
July, 1992 Assistant Pr<strong>of</strong>essor, Section <strong>of</strong> Endocrinology, <strong>Department</strong> <strong>of</strong> <strong>Medicine</strong>,<br />
University <strong>of</strong> Chicago, Chicago, IL<br />
January, 1990 Chief Resident and Instructor, <strong>Department</strong> <strong>of</strong> <strong>Medicine</strong>, University <strong>of</strong><br />
Chicago, Chicago, IL<br />
Honors and Awards<br />
2008 Best Doctors in America 2008<br />
2007 WCHL Hometown Hero, Chapel Hill, NC<br />
2007 Best Doctors in America 2007<br />
2007 Business North Carolina, “Top Doctors – Endocrinology/Metabolism”<br />
2006 Best Doctors in America 2006-2007<br />
2006 Business North Carolina, “Top Doctors – Endocrinology/Metabolism”<br />
2005 Best Doctors in America 2005-2006<br />
2004 Best Doctors in America 2004-2005<br />
2003 Best Doctors in America 2003-2004<br />
2003 Business North Carolina, “Top Doctors – Endocrinology”<br />
2002 Business North Carolina, One <strong>of</strong> “<strong>the</strong> top practitioners” in North Carolina<br />
2002 Robert J Glaser Clinical Star, Washington University, St. Louis, MO<br />
2002 Best Doctors in America 2002-2003<br />
2001 Best Doctors in America 2001-2002<br />
2000 Fellowship, American College <strong>of</strong> Endocrinology<br />
1998 Mary Jane Kugel Award, Juvenile Diabetes Foundation International<br />
1997 HOPE Health Corps Award "In recognition <strong>of</strong> your contribution in <strong>the</strong> area <strong>of</strong> medical<br />
education"<br />
1997 American Diabetes Association Recognition "For outstanding leadership in <strong>the</strong> midst <strong>of</strong><br />
change . . ."<br />
1996 American Health, "Best Doctors in America"<br />
1994 University <strong>of</strong> Chicago, Internal <strong>Medicine</strong> Resident's Teaching Recognition<br />
1994 University <strong>of</strong> Chicago Pritzker School <strong>of</strong> <strong>Medicine</strong>, Medical Student Teaching Award -<br />
Class <strong>of</strong> 1994 Composite Picture<br />
1993 University <strong>of</strong> Chicago, Internal <strong>Medicine</strong> Resident's Teaching Recognition<br />
1992 Young Investigator Award, American Diabetes Assoc., Nor<strong>the</strong>rn Illinois Affiliate<br />
1991 Syntex/<strong>Medicine</strong> Clinical Excellence Award<br />
1989 Young Investigator Award, American Diabetes Assoc., Nor<strong>the</strong>rn Illinois Affiliate<br />
1984 Novo Award, Immunology <strong>of</strong> Diabetes '84 International Symposium, Rome, Italy
<strong>Buse</strong>, Curriculum Vitae p. 3 <strong>of</strong> 29 Updated: August 2008<br />
Biobliography<br />
Books and Chapters:<br />
1. <strong>Buse</strong> JB. Management <strong>of</strong> type 2 diabetes mellitus. In: Endocrinology, 6 th edition (Leslie<br />
DeGroot and J. Larry Jameson, eds.). Elsevier, Philadelphia, PA. In press<br />
2. <strong>Buse</strong> JB, Polonsky KS, Burant CF. Type 2 diabetes mellitus. In: Williams Textbook <strong>of</strong><br />
Endocrinology, 11 th ed (HM Kronenberg, S Melmed, KS Polonsky, PR Larsen, eds). Elsevier<br />
Science, Philadelphia, PA. pp. 1329-89, 2008.<br />
3. Eisenbarth GS, Polonsky KS, <strong>Buse</strong> JB. Type 1 diabetes mellitus. In: Williams Textbook <strong>of</strong><br />
Endocrinology, 11 th ed (HM Kronenberg, S Melmed, KS Polonsky, PR Larsen, eds). Elsevier<br />
Science, Philadelphia, PA. pp. 1391-1416, 2008.<br />
4. <strong>Buse</strong> JB. Scope <strong>of</strong> <strong>the</strong> problem: The diabetes-metabolic epidemic. In: Clinical Diabetes:<br />
Translating Research into Practice. (editor, Vivian Fonseca). Saunders, Philadelphia, PA.<br />
pp. 1-5, 2006.<br />
5. <strong>Buse</strong> JB. Management <strong>of</strong> type 2 diabetes mellitus. In: Endocrinology, 5 th edition (Leslie<br />
DeGroot and J. Larry Jameson, eds.). Elsevier, Philadelphia, PA. pp 1231-48, 2005.<br />
6. <strong>Buse</strong> JB. Diabetes mellitus in adults. In: Conn’s Current Therapy, 2005 (Robert E Rakel<br />
and Edward T Bope, editors). Saunders, Philadelphia, PA. pp. 661-670, 2005.<br />
7. American Diabetes Association (J <strong>Buse</strong>, contributing editor). Medical Management <strong>of</strong> Type<br />
2 Diabetes, 5 th Edition (Charles F. Burant, Ed.) American Diabetes Association, 2004. 141<br />
pages.<br />
8. <strong>Buse</strong> JB. Rationale for standards <strong>of</strong> care. In: The Cadre Handbook <strong>of</strong> Diabetes<br />
Management (WT Cefalu, JE Gerich, D LeRoith, eds). Medical Information Press, New<br />
York, NY, 2004. pp. 29-51.<br />
9. <strong>Buse</strong> JB and Polonsky KS. Ketoacidosis, HONKC and hypoglycemia. In: Principles <strong>of</strong><br />
Critical Care <strong>Medicine</strong>, 3 rd Edition (JB Hall, GA Schmidt, LDH Woods, eds). McGraw Hill,<br />
New York, NY. 1209-17, 2005.<br />
10. <strong>Buse</strong> JB. Diabetes mellitus and its complications. In: Netter’s Internal <strong>Medicine</strong>, (MS<br />
Runge and MA Greganti, eds). Icon Learning Systems LLC, Teterboro, NJ. pp. 184-194,<br />
2003.<br />
11. <strong>Buse</strong> JB, Polonsky KS and Burant CF. Type 2 diabetes mellitus. In: Williams Textbook <strong>of</strong><br />
Endocrinology, 10 th ed (PR Larsen, HM Kronenberg, S Melmed, KS Polonsky, eds). Elsevier<br />
Science, Philadelphia, PA. pp. 1427-1483, 2003.<br />
12. Eisenbarth GS, Polonsky KS, <strong>Buse</strong> JB. Type 1 diabetes mellitus. In: Williams Textbook <strong>of</strong><br />
Endocrinology, 10 th ed (PR Larsen, HM Kronenberg, S Melmed, KS Polonsky, eds).<br />
Elsevier Science. pp. 1485-1508, 2003.<br />
13. <strong>Buse</strong> JB. Insulin Resistance Syndrome. In: Blackwell Science, Oxford, UK. pp. 7-10, 2000.<br />
14. <strong>Buse</strong> JB. The Patient with Diabetes. In: Management <strong>of</strong> Office Emergencies (C.W. Barton,<br />
ed). McGraw Hill, New York. pp. 73-95, 1999.<br />
15. Nathan DM and <strong>Buse</strong> JB. Monitoring Diabetes. In: Therapy for Diabetes Mellitus and<br />
Related Disorders, 3rd ed (H Lebovitz, ed). American Diabetes Association, Alexandria,<br />
VA. Pp 109-117, 1998.<br />
16. <strong>Buse</strong> JB, contributing editor. Medical Management <strong>of</strong> Type 2 Diabetes, 4th ed (B<br />
Zimmerman, ed). American Diabetes Association, Alexandria, VA. 1998. 141 pages.<br />
17. <strong>Buse</strong> JB and Polonsky KS. Diabetic ketoacidosis, hyperglycemic hyperosmolar nonketotic<br />
coma, and hypoglycemia. In: Principles <strong>of</strong> Critical Care <strong>Medicine</strong>, 2 nd Edition. (JB Hall,<br />
GA Schmidt, LDH Woods, eds). McGraw Hill, New York. pp. 1183-1193, 1998.
<strong>Buse</strong>, Curriculum Vitae p. 4 <strong>of</strong> 29 Updated: August 2008<br />
18. Doerr ME and <strong>Buse</strong> JB. Management <strong>of</strong> Complications <strong>of</strong> Diabetes. In: Manual <strong>of</strong> Clinical<br />
Problems in Adult Ambulatory Care, 3rd ed (L Dornbrand, AJ Hoole, RH Fletcher, eds).<br />
Lippincott-Raven Publishers, Philadelphia. pp. 371-5, 1997.<br />
19. Doerr ME and <strong>Buse</strong> JB. Management <strong>of</strong> Type II Diabetes. In: Manual <strong>of</strong> Clinical Problems<br />
in Adult Ambulatory Care, 3rd ed (L Dornbrand, AJ Hoole, RH Fletcher, eds). Lippincott-<br />
Raven Publishers, Philadelphia. pp. 364-71, 1997.<br />
20. <strong>Buse</strong> JB and Doerr ME. Diabetic Ketoacidosis. In: Conn's Current Therapy 1997 (RE<br />
Rakel, ed). W.B. Saunders Co., Philadelphia, PA. pp. 553-7, 1997.<br />
21. <strong>Buse</strong> J and Doerr ME. The Pancreas. In: Handbook <strong>of</strong> Endocrinology, 3nd ed (GH Gass<br />
and HM Kaplan, eds). CRC Press, Boca Raton. pp 297-314, 1996.<br />
22. <strong>Buse</strong> JB and Polonsky KS. Ketoacidosis, HONKC and hypoglycemia. In: Principles <strong>of</strong><br />
Critical Care <strong>Medicine</strong> (JB Hall, GA Schmidt, LDH Woods, eds). McGraw Hill, New York,<br />
NY. pp 1966-76, 1992.<br />
23. Bell GI, <strong>Buse</strong> JB, Fukumoto H, Kayano T, Seino S. Glucose transporters - molecular<br />
structure and function In: Genes and Gene Products in <strong>the</strong> Development <strong>of</strong> Diabetes<br />
Mellitus - Basic and Clinical Aspects (J Nerup T Mandrup-Poulsen & B Hokfelt eds).<br />
Excerpta Medica, Amsterdam. pp. 287-97, 1990.<br />
24. Eisenbarth GS, Jackson R, Srikanta S, Powers A, <strong>Buse</strong> J, Mori H. Utilization <strong>of</strong> monoclonal<br />
antibody techniques to study Type 1 (insulin dependent) diabetes mellitus. In: Immunology<br />
in Diabetes (D Andreani U DiMario KG Federlin LG Heding eds). Kimpton Medical<br />
Publications, London. pp 143-57, 1984.<br />
25. Margolius HS and <strong>Buse</strong> JB. The renal kallikrein-kinin system. In: Hormonal Function and<br />
<strong>the</strong> Kidney (BM Brenner and JH Stein eds). Churchill Livingstone, New York. pp 115-45,<br />
1979.<br />
Refereed Original Research:<br />
1. <strong>Buse</strong> JB, Caprio S, Cefalu WT, Ceriello A, Del Prato S, Inzucchi SE, McLaughlin S, Phillips<br />
GL 2nd, Robertson RP, Rubino F, Kahn R, Kirkman MS. How do we define cure <strong>of</strong><br />
diabetes? Diabetes Care. 2009; 32:2133-5.<br />
2. Mount DL, Feeney P, Fabricatore AN, Coday M, Bahnson J, Byington R, Phelan S, Wilmoth<br />
S, Knowler WC, Hramiak I, Osei K, Sweeney ME, Espeland MA; Look AHEAD and<br />
ACCORD Research Groups. Constructing common cohorts from trials with overlapping<br />
eligibility criteria: implications for comparing effect sizes between trials. Clin Trials 6:416-<br />
29, 2009.<br />
3. Ambrosius WT, Danis RP, G<strong>of</strong>f Jr. DC, Greven CM, Gerstein HC, Cohen RM, Riddle MC,<br />
Miller ME, <strong>Buse</strong> JB, Bonds DE, Peterson KA, Rosenberg YD, Perdue LH, Esser BA,<br />
Seaquist LA, Felicetta JV, Chew EY for <strong>the</strong> ACCORD Study Investigators. Lack <strong>of</strong><br />
association between thiazolidinediones and macular edema in type 2 diabetes: The ACCORD<br />
Eye Study. Archives <strong>of</strong> Ophthalmology, in press, expected publication January 2010.<br />
4. Dungan K, <strong>Buse</strong> JB, Ratner RE. Effects <strong>of</strong> <strong>the</strong>rapy in type 1 and type 2 diabetes mellitus<br />
with a peptide derived from islet neogenesis associated protein (INGAP). Diabetes Metab<br />
Res Rev. 2009; 25:558-65.<br />
5. Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC,Evans<br />
GW, Gerstein HC, Holman RR, Moritz TE, Neal BC, Ninomiya T, Patel AA, Paul SK,<br />
Travert F, Woodward M. Intensive glucose control and macrovascular outcomes in type 2<br />
diabetes. Diabetologia. 2009 Aug 5. Epub.
<strong>Buse</strong>, Curriculum Vitae p. 5 <strong>of</strong> 29 Updated: August 2008<br />
6. <strong>Buse</strong> J and Hirst K. The HEALTHY study: introduction. International Journal <strong>of</strong> Obesity.<br />
2009 33 (suppl 4):1-2<br />
7. The HEALTHY Study Group. HEALTHY study rationale, design and methods: moderating<br />
risk <strong>of</strong> type 2 diabetes in multi-ethnic middle school students. International Journal <strong>of</strong><br />
Obesity. 2009 33 (suppl 4):4-20<br />
8. Drews KL, Harrell JS, Thompson D, Mazzuto SL, Ford EG, Carter M, Ford DA, Yin Z,<br />
Jessup AN, Roullet J-B, for <strong>the</strong> HEALTHY Study Group. Recruitment and retention<br />
strategies and methods in <strong>the</strong> HEALTHY study. International Journal <strong>of</strong> Obesity. 2009 33<br />
(suppl 4):21-28.<br />
9. Gillis B, Mobley C, Stadler DD, Hartstein J, Virus A, Volpe SL, El ghormli L, Staten MA,<br />
Bridgman J, McCormick S, for <strong>the</strong> HEALTHY Study Group. Rationale, design and methods<br />
<strong>of</strong> <strong>the</strong> HEALTHY study nutrition intervention component. International Journal <strong>of</strong> Obesity.<br />
2009 33 (suppl 4):29-36<br />
10. McMurray RG, Bassin S, Jago R, Bruecker S, Moe EL, Murray T, Mazzuto SL, Volpe SL,<br />
for <strong>the</strong> HEALTHY Study Group. Rationale, design and methods <strong>of</strong> <strong>the</strong> HEALTHY study<br />
physical education intervention component. International Journal <strong>of</strong> Obesity. 2009 33 (suppl<br />
4):37-43<br />
11. Venditti EM, Elliot DL, Faith MS, Firrell LS, Giles CM, Goldberg L, Marcus MD, Schneider<br />
M, Solomon S, Thompson D, Yin Z, for <strong>the</strong> HEALTHY Study Group. Rationale, design and<br />
methods <strong>of</strong> <strong>the</strong> HEALTHY study behavior intervention component. International Journal <strong>of</strong><br />
Obesity. 2009 33 (suppl 4):44-51<br />
12. DeBar LL, Schneider M, Ford EG, Hernandez AE, Showell B, Drews KL, Moe EL, Gillis B,<br />
Jessup AN, Stadler DD, White M, for <strong>the</strong> HEALTHY Study Group. Social marketing-based<br />
communications to integrate and support <strong>the</strong> HEALTHY study intervention. International<br />
Journal <strong>of</strong> Obesity. 2009 33 (suppl 4):52-59<br />
13. Schneider M, Hall WJ, Hernandez AE, Hindes K, Montez G, Pham T, Rosen L, Sleigh A,<br />
Thompson D, Volpe SL, Zevel<strong>of</strong>f A, Steckler A, for <strong>the</strong> HEALTHY Study Group. Rationale,<br />
design and methods for process evaluation in <strong>the</strong> HEALTHY study. International Journal <strong>of</strong><br />
Obesity. 2009 33 (suppl 4):60-67<br />
14. Jago R, McMurray RG, Bassin S, Pyle L, Bruecker S, Jakicic JM, Moe E, Murray T, Volpe<br />
S. Modifying middle school physical education: piloting strategies to increase physical<br />
activity. Pediatric Exercise Science. 2009, 21, 171-185.<br />
15. HEALTHY Study Group, Kaufman FR, Hirst K, Linder B, Baranowski T, Cooper DM,<br />
Foster GD, Goldberg L, Harrell JS, Marcus MD, Treviño RP. Risk factors for type 2 diabetes<br />
in a sixth- grade multiracial cohort: <strong>the</strong> HEALTHY study. Diabetes Care. 2009; 32:953-5.<br />
16. Zinman B, Gerich J, <strong>Buse</strong> J, Lewin A, Schwartz SL, Raskin P, et al. Efficacy and safety <strong>of</strong><br />
<strong>the</strong> human GLP-1 analog liraglutide in combination with metformin and TZD in patients<br />
with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care 2009; 32: 1224–1230.<br />
17. <strong>Buse</strong> JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L;<br />
for <strong>the</strong> LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2<br />
diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).<br />
Lancet. 2009; 374(9683):39-47.<br />
18. Young LH, Wackers FJ, Chyun DA, Davey JA, Barrett EJ, Taillefer R, Heller GV,<br />
Iskandrian AE, Wittlin SD, Filipchuk N, Ratner RE, Inzucchi SE; DIAD Investigators.<br />
Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with<br />
type 2 diabetes: <strong>the</strong> DIAD study: a randomized controlled trial. JAMA. 2009; 301:1547-55.
<strong>Buse</strong>, Curriculum Vitae p. 6 <strong>of</strong> 29 Updated: August 2008<br />
19. Kernan WN, Viscoli CM, Demarco D, Mendes B, Shrauger K, Schindler JL, McVeety JC,<br />
Sicklick A, Moalli D, Greco P, Bravata DM, Eisen S, Resor L, Sena K, Story D, Brass LM,<br />
Furie KL, Gutmann L, Hinnau E, Gorman M, Lovejoy AM, Inzucchi SE, Young LH,<br />
Horwitz RI; IRIS Trial Investigators. Boosting enrollment in neurology trials with Local<br />
Identification and Outreach Networks (LIONs). Neurology. 2009; 72(15):1345-51.<br />
20. <strong>Buse</strong> JB, Wolffenbuttel BH, Herman WH, Shemonsky NK, Jiang HH, Fahrbach JL, Scism-<br />
Bacon JL, Martin SA. DURAbility <strong>of</strong> basal versus lispro mix 75/25 insulin efficacy<br />
(DURABLE) trial 24-week results: safety and efficacy <strong>of</strong> insulin lispro mix 75/25 versus<br />
insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes.<br />
Diabetes Care. 2009; 32:1007-13.<br />
21. Herman WH, Dungan KM, Wolffenbuttel BH, <strong>Buse</strong> JB, Fahrbach JL, Jiang H, Martin S.<br />
Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1,5anhydroglucitol<br />
in over 2000 patients with type 2 diabetes. J Clin Endocrinol Metab. 2009;<br />
94:1689-94.<br />
22. Califf RM, Boolell M, Haffner SM, Be<strong>the</strong>l MA, McMurray J, Duggal A, Holman RR;<br />
NAVIGATOR Study Group. Prevention <strong>of</strong> diabetes and cardiovascular disease in patients<br />
with impaired glucose tolerance: rationale and design <strong>of</strong> <strong>the</strong> Nateglinide And Valsartan in<br />
Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. Am Heart J. 2008<br />
Oct;156(4):623-32.<br />
23. Schneider A, Neas L, Herbst MC, Case M, Williams RW, Cascio W, Hinderliter A, Holguin<br />
F, <strong>Buse</strong> JB, Dungan K, Styner M, Peters A, Devlin RB. Endo<strong>the</strong>lial dysfunction: associations<br />
with exposure to ambient fine particles in diabetic individuals. Environ Health Perspect.<br />
2008; 116:1666-74.<br />
24. Drucker DJ, <strong>Buse</strong> JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, Porter L for <strong>the</strong><br />
DURATION-1 Study Group. Exenatide once weekly versus twice daily for <strong>the</strong> treatment <strong>of</strong><br />
type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008; 372:1240-50.<br />
25. Studies to Treat or Prevent Pediatric Type 2 Diabetes Prevention Study Group. Prevalence<br />
<strong>of</strong> <strong>the</strong> metabolic syndrome among a racially/ethnically diverse group <strong>of</strong> U.S. eighth-grade<br />
adolescents and associations with fasting insulin and homeostasis model assessment <strong>of</strong><br />
insulin resistance levels. Diabetes Care. 2008; 31:2020-5.<br />
26. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME,<br />
Byington RP, G<strong>of</strong>f DC Jr, Bigger JT, <strong>Buse</strong> JB, Cushman WC, Genuth S, Ismail-Beigi F,<br />
Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects <strong>of</strong> intensive<br />
glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358:2545-59.<br />
27. Huizinga MM, Elasy TA, Wallston KA, Cavanaugh K, Davis D, Gregory RP, Fuchs LS,<br />
Malone R, Cherrington A, Dewalt DA, <strong>Buse</strong> J, Pignone M, Rothman RL. Development and<br />
validation <strong>of</strong> <strong>the</strong> Diabetes Numeracy Test (DNT). BMC Health Serv Res. 2008; 8:96.<br />
28. Hartstein J, Cullen KW, Reynolds KD, Harrell J, Resnicow K, Kennel P for <strong>the</strong> STOPP-T2D<br />
Prevention Study Group. Impact <strong>of</strong> portion-size control for school a la carte items: changes<br />
in kilocalories and macronutrients purchased by middle school students. J Am Diet Assoc.<br />
2008; 108:140-4.<br />
29. Origin Trial Investigators, Gerstein H, Yusuf S, Riddle MC, Ryden L, Bosch J. Rationale,<br />
design, and baseline characteristics for a large international trial <strong>of</strong> cardiovascular disease<br />
prevention in people with dysglycemia: <strong>the</strong> ORIGIN Trial (Outcome Reduction with an<br />
Initial Glargine Intervention). Am Heart J. 2008; 155:26-32
<strong>Buse</strong>, Curriculum Vitae p. 7 <strong>of</strong> 29 Updated: August 2008<br />
30. Farkouh ME, Dangas G, Leon MB, Smith C, Nesto R, <strong>Buse</strong> JB, Cohen DJ, Mahoney E,<br />
Sleeper L, King S 3rd, Domanski M, McKinlay S, Fuster V. Design <strong>of</strong> <strong>the</strong> Future<br />
REvascularization Evaluation in patients with Diabetes mellitus: Optimal management <strong>of</strong><br />
Multivessel disease (FREEDOM) Trial. Am Heart J. 2008; 155:215-23.<br />
31. Klon<strong>of</strong>f DC, <strong>Buse</strong> JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME, Maggs<br />
DG. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic<br />
biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin.<br />
2008; 24:275-86.<br />
32. Wackers FJ, Chyun DA, Young LH, Heller GV, Iskandrian AE, Davey JA, Barrett EJ,<br />
Taillefer R, Wittlin SD, Filipchuk N, Ratner RE, Inzucchi SE; Detection <strong>of</strong> Ischemia in<br />
Asymptomatic Diabetics (DIAD) Investigators. Resolution <strong>of</strong> asymptomatic myocardial<br />
ischemia in patients with type 2 diabetes in <strong>the</strong> Detection <strong>of</strong> Ischemia in Asymptomatic<br />
Diabetics (DIAD) study. Diabetes Care. 2007; 30:2892-8.<br />
33. Dungan KM, Guster T, DeWalt DA, <strong>Buse</strong> JB. A comparison <strong>of</strong> lipid and lipoprotein<br />
measurements in <strong>the</strong> fasting and nonfasting states in patients with type 2 diabetes. Current<br />
Medical Research and Opinion 2007; 23:2689-2695.<br />
34. Deeg MA, <strong>Buse</strong> JB, Goldberg RB, Kendall DM, Zagar AJ, Jacober SJ, Khan MA, Perez AT,<br />
Tan MH for <strong>the</strong> GLAI Study Investigators. Pioglitazone and rosiglitazone have different<br />
effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes<br />
and dyslipidemia. Diabetes Care 2007; 30:2458-64.<br />
35. Byington RP, Genuth S, Friedewald WT, Simons-Morton DG. Introduction (to <strong>the</strong> ACCORD<br />
Supplement). Am J Cardiol 2007;99[suppl]:1i-3i.<br />
36. G<strong>of</strong>f DC, Gerstein HC, Ginsberg HN, Cushman WC, Margolis KL, Byington RP, <strong>Buse</strong> JB,<br />
Genuth S, Probstfield JL, Simons-Morton DG for <strong>the</strong> ACCORD Study Group. Prevention <strong>of</strong><br />
cardiovascular disease in persons with type 2 diabetes mellitus: Current knowledge and<br />
rationale for <strong>the</strong> Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J<br />
Cardiol 2007;99[suppl]:4i-20i.<br />
37. ACCORD Study Group (Writing Committee: <strong>Buse</strong> JB, Bigger JT, Byington RP, Cooper LS,<br />
Cushman WC, Friedewald WT, Genuth S, Gerstein HC, Ginsberg HN, G<strong>of</strong>f DC, Grimm RH,<br />
Jr, Margolis KL, Probstfield JL, Simons-Morton DG, Sullivan MD). Action to Control<br />
Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and methods. Am J Cardiol<br />
2007;99[suppl]:21i-33i.<br />
38. Gerstein, HC, Riddle MC, Kendall DM, Cohen RM, Goland R, Feinglos MN, Kirk JK,<br />
Hamilton BP, Ismail-Beigi F, Feeney P, for <strong>the</strong> ACCORD Study Group. Glycemia treatment<br />
strategies in <strong>the</strong> Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J<br />
Cardiol 2007;99[suppl]:34i-43i.<br />
39. Cushman WC, Grimm RH, Cutler JA, Evans GW, Capes S, Corson MA, Sadler LS,<br />
Alderman MH, Peterson K, Bertoni A, Basile JN, for <strong>the</strong> ACCORD Study Group. Rationale<br />
and design for <strong>the</strong> blood pressure intervention <strong>of</strong> <strong>the</strong> Action to Control Cardiovascular Risk<br />
in Diabetes (ACCORD) trial. Am J Cardiol 2007;99[suppl]:44i-55i.<br />
40. Ginsberg HN, Bonds DE, Lovato LC, Crouse JR, Elam MB, Linz PE, O’Connor PJ, Leiter<br />
LA, Weiss D, Lipkin E, Fleg JL, for <strong>the</strong> ACCORD Study Group. Evolution <strong>of</strong> <strong>the</strong> lipid trial<br />
protocol <strong>of</strong> <strong>the</strong> Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J<br />
Cardiol 2007;99[suppl]:56i-67i.<br />
41. Kingry C, Bastien A, Booth G, Geraci TS, Kirpach BR, Lovato LC, Margolis KL, Rosenberg<br />
Y, Sperl-Hillen JM, Vargo L, Williamson JD, Probstfield JL, for <strong>the</strong> ACCORD Study Group.
<strong>Buse</strong>, Curriculum Vitae p. 8 <strong>of</strong> 29 Updated: August 2008<br />
Recruitment strategies in <strong>the</strong> Action to Control Cardiovascular Risk in Diabetes (ACCORD)<br />
Trial. Am J Cardiol 2007;99[suppl]:68i-79i.<br />
42. Bonds DE, Kurashige EM, Bergenstal R, Brillon D, Domanski M, Felicetta JL, Fonseca VA,<br />
Hall K, Hramriak I, Miller ME, Osei K, Simons-Morton DG, for <strong>the</strong> ACCORD Study Group.<br />
Severe hypoglycemia monitoring and risk management procedures in <strong>the</strong> Action to Control<br />
Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99[suppl]:80i-89i.<br />
43. Sullivan MD, Anderson RT, Aron D, Atkinson HH, Bastien A, Chen GJ, Feeney P, Gafni A,<br />
Hwang W, Katz LA, Narayan KMV, Nwachuku C, O’Connor PJ, Zhang P, for <strong>the</strong> ACCORD<br />
Study Group. Health-related quality <strong>of</strong> life and cost-effectiveness components <strong>of</strong> <strong>the</strong> Action<br />
for Control Cardiovascular Risk in Diabetes (ACCORD) trial: rationale and design. Am J<br />
Cardiol 2007;99[suppl]:90i-102i.<br />
44. Chew EY, Ambrosius WT, Howard LT, Greven CM, <strong>John</strong>son S, Danis RP, Davis MD,<br />
Genuth S, Domanski M, for <strong>the</strong> ACCORD Study Group. Rationale, design and methods <strong>of</strong><br />
<strong>the</strong> Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD-Eye). Am J<br />
Cardiol 2007;99[suppl]:103i-111i.<br />
45. Williamson JD, Miller ME, Bryan N, Lazar RM, Coker LH, <strong>John</strong>son J, Cukierman T,<br />
Horowitz KR, Murray A, Launer LJ, for <strong>the</strong> ACCORD Study Group. The Action to Control<br />
Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale,<br />
design and methods. Am J Cardiol 2007;99[suppl]:112i-122i.<br />
46. Cullen KW, Hartstein J, Reynolds KD, Vu M, Resnicow K, Greene N, White MA, Studies to<br />
Treat or Prevent Pediatric Type 2 Diabetes Prevention Study Group. Improving <strong>the</strong> school<br />
food environment: results from a pilot study in middle schools. J Am Diet Assoc. 107:484-9,<br />
2007.<br />
47. <strong>Buse</strong> JB, Klon<strong>of</strong>f DC, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Maggs DG, Wintle<br />
ME. Metabolic effects <strong>of</strong> two years <strong>of</strong> exenatide treatment on diabetes, obesity, and hepatic<br />
biomarkers in patients with type 2 diabetes: an interim analysis <strong>of</strong> data from <strong>the</strong> open-label,<br />
uncontrolled extension <strong>of</strong> three double-blind, placebo-controlled trials. Clinical<br />
Therapeutics 29:139-53, 2007.<br />
48. Knopp RH, d’Emden M, Smilde JG, Pocock SJ and on behalf <strong>of</strong> <strong>the</strong> ASPEN Study Group.<br />
Efficacy and Safety <strong>of</strong> Atorvastatin in <strong>the</strong> Prevention <strong>of</strong> Cardiovascular End Points in<br />
Subjects With Type 2 Diabetes: The Atorvastatin Study for Prevention <strong>of</strong> Coronary Heart<br />
Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN). Diabetes Care<br />
29: 1478-1485, 2006.<br />
49. Dungan KM, <strong>Buse</strong> JB, Largay J, Kelly MM, Button EA, Kato S, Wittlin S. 1,5anhydroglucitol<br />
and postprandial hyperglycemia as measured by continuous glucose<br />
monitoring system in moderately controlled patients with diabetes. Diabetes Care 29:1214-9,<br />
2006.<br />
50. Jago R, Harrell JS, McMurray RG, Edelstein S, El Ghormli L, Bassin S. Prevalence <strong>of</strong><br />
abnormal lipid and blood pressure values among an ethnically diverse population <strong>of</strong> eighthgrade<br />
adolescents and screening implications. Pediatrics 117:2065-73, 2006.<br />
51. The STOPP-T2D Prevention Study Group. Presence <strong>of</strong> diabetes risk factors in a large U.S.<br />
eighth grade cohort. Diabetes Care. 29:212-7, 2006.<br />
52. <strong>Buse</strong> JB, Rubin CJ, Frederich R, Viraswami-Appanna K, Lin KC, Montoro R, Shockey G,<br />
Davidson JA. Muraglitazar, a dual (alpha/gamma) PPAR activator: A randomized, doubleblind,<br />
placebo-controlled, 24-week mono<strong>the</strong>rapy trial in adult patients with type 2 diabetes.<br />
Clin Ther. 27:1181-95, 2005.
<strong>Buse</strong>, Curriculum Vitae p. 9 <strong>of</strong> 29 Updated: August 2008<br />
53. Goldberg RB, Kendall DM, Deeg MA, <strong>Buse</strong> JB, Zagar AJ, Pinaire JA, Tan MH, Khan MA,<br />
Perez AT, Jacober SJ; GLAI Study Investigators. A comparison <strong>of</strong> lipid and glycemic effects<br />
<strong>of</strong> pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes<br />
Care 28:1547-54, 2005.<br />
54. Grant RW, <strong>Buse</strong> JB, Meigs JB; University HealthSystem Consortium (UHC) Diabetes<br />
Benchmarking Project Team. Quality <strong>of</strong> diabetes care in U.S. academic medical centers: low<br />
rates <strong>of</strong> medical regimen change. Diabetes Care 28:337-442, 2005.<br />
55. Malhotra A, Coon H, Feitosa MF, Li WD, North KE, Price RA, Bouchard C, Hunt SC,<br />
Wolford JK, The American Diabetes Association GENNID Study Group. Meta-analysis <strong>of</strong><br />
genome-wide linkage studies for quantitative lipid traits in African Americans. Hum Mol<br />
Genet 14:3955-62, 2005.<br />
56. Malhotra A, Wolford JK, American Diabetes Association GENNID Study Group. Analysis<br />
<strong>of</strong> quantitative lipid traits in <strong>the</strong> genetics <strong>of</strong> NIDDM (GENNID) study. Diabetes 54:3007-<br />
14, 2005.<br />
57. Cavazzoni P, Mukhopadhyay N, Carlson C, Breier A, <strong>Buse</strong> J. Retrospective analysis <strong>of</strong> risk<br />
factors in patients with treatment-emergent diabetes during clinical trials <strong>of</strong> antipsychotic<br />
medications. Br J Psychiatry Suppl. 47:S94-101, 2004. Erratum in: Br J Psychiatry 186:449,<br />
2005.<br />
58. <strong>Buse</strong> JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD; Exenatide-113 Clinical Study<br />
Group. Effects <strong>of</strong> exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylureatreated<br />
patients with type 2 diabetes. Diabetes Care 27:2628-35, 2004.<br />
59. Wackers FJT, Young LH, Inzucchi SE, Chyun DA, Davey JA, Barrett EJ, Taillefer R,<br />
Wittlin SD, Heller GV, Filipchuk N, Engel S, Ratner RE, Iskandrian AE for for <strong>the</strong> Detection<br />
<strong>of</strong> Ischemia in Asymptomatic Diabetics (DIAD) Investigators. Detection <strong>of</strong> Silent<br />
Myocardial Ischemia in Asymptomatic Diabetic Subjects: The DIAD study. Diabetes Care<br />
27: 1954-61, 2004.<br />
60. Bolton WK, Cattran DC, Williams ME, Adler SG, Appel GB, Cartwright K, Foiles PG,<br />
Freedman BI, Raskin P, Ratner RE, Spinowitz BS, Whittier FC, Wuerth J-P for <strong>the</strong> ACTION<br />
I Investigator Group. Randomized trial <strong>of</strong> an inhibitor <strong>of</strong> formation <strong>of</strong> advanced glycation<br />
end products in diabetic nephropathy. American Journal <strong>of</strong> Nephrology 24:32-40, 2004.<br />
61. Kolterman OG, <strong>Buse</strong> JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D,<br />
Aisporna M, Wang Y, Baron AD. Syn<strong>the</strong>tic exendin-4 (exenatide) significantly reduces<br />
postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol<br />
Metab. 88:3082-9, 2003.<br />
62. <strong>Buse</strong> JB, Cavazzoni P, Hornbuckle K, Hutchins D, Breier A, Jovanovic L. A retrospective<br />
cohort study <strong>of</strong> diabetes mellitus and antipsychotic treatment in <strong>the</strong> United States. Journal <strong>of</strong><br />
Clinical Epidemiology 56:164-70, 2003.<br />
63. Duggirala R, Almasy L, Blangero J, Jenkinson CP, Arya R, DeFronzo RA, Stern MP,<br />
O'Connell P, American Diabetes Association GENNID Study Group. Fur<strong>the</strong>r evidence for a<br />
type 2 diabetes susceptibility locus on chromosome 11q. Genet Epidemiol 24:240-2, 2003.<br />
64. Jensen CC, Cnop M, Hull RL, Fujimoto WY, Kahn SE, American Diabetes Association<br />
GENNID Study Group. Beta-cell function is a major contributor to oral glucose tolerance in<br />
high-risk relatives <strong>of</strong> four ethnic groups in <strong>the</strong> U.S. Diabetes 51:2170-8, 2002.<br />
65. Ehm MG, Karnoub MC, Sakul H, Gottschalk K, Holt DC, Weber JL, Vaske D, Briley D,<br />
Briley L, Kopf J, McMillen P, Nguyen Q, Reisman M, Lai EH, Joslyn G, Shepherd NS, Bell<br />
C, Wagner MJ, Burns DK, American Diabetes Association GENNID Study Group. Genetics
<strong>Buse</strong>, Curriculum Vitae p. 10 <strong>of</strong> 29 Updated: August 2008<br />
<strong>of</strong> NIDDM. Genomewide search for type 2 diabetes susceptibility genes in four American<br />
populations. Am J Hum Genet 66:1871-81, 2000. Erratum in: Am J Hum Genet 70:284,<br />
2002.<br />
66. Merz CN, <strong>Buse</strong> JB, Tuncer D, Twillman GB: Physician attitudes and practices and patient<br />
awareness <strong>of</strong> <strong>the</strong> cardiovascular complications <strong>of</strong> diabetes. Journal <strong>of</strong> <strong>the</strong> American College<br />
<strong>of</strong> Cardiology 40:1877-81, 2002.<br />
67. Grundy SM, Vega GL, McGovern ME, Tulloch BR, Kendall DM, Fitz-Patrick D, Ganda OP,<br />
Rosenson RS, <strong>Buse</strong> JB, Robertson DD, Sheehan JP, and <strong>the</strong> Diabetes Multicenter Research<br />
Group. Efficacy, safety, and tolerability <strong>of</strong> once-daily niacin for <strong>the</strong> treatment <strong>of</strong><br />
dyslipidemia associated with type 2 diabetes: results <strong>of</strong> <strong>the</strong> assessment <strong>of</strong> diabetes control<br />
and evaluation <strong>of</strong> <strong>the</strong> efficacy <strong>of</strong> Niaspan trial. Archives <strong>of</strong> Internal <strong>Medicine</strong> 162:1568-76,<br />
2002.<br />
68. <strong>Buse</strong> J, Hart K, Minasi L on behalf <strong>of</strong> <strong>the</strong> PROTECT Study Group. The PROTECT study:<br />
final results <strong>of</strong> a large multicenter postmarketing study in patients with type 2 diabetes.<br />
Clinical Therapeutics 20(2):257-69, 1998.<br />
69. <strong>Buse</strong> J, Gumbiner B, Mathias NP, Nelson DM, Whitcomb RW for <strong>the</strong> Troglitazone Study<br />
Group. Troglitazone use in insulin-treated type 2 diabetic patients. Diabetes Care<br />
21(9):1455-61, 1998.<br />
70. Ghazzi MN, Perez JE, Antonucci TK, Driscoll JH, Huang SM, Faja BW, The Troglitazone<br />
Study Group, Whitcomb RW. Cardiac and glycemic benefits <strong>of</strong> troglitazone treatment in<br />
NIDDM. Diabetes 46:433-9, 1997.<br />
71. Raffel LJ, Robbins DC, Norris JM, Boerwinkle E, DeFronzo RA, Elbein SC, Fujimoto W,<br />
Hanis CL, Kahn SE, Permutt MA, Chiu KC, Cruz J, Ehrmann DA, Robertson RP, Rotter JI,<br />
<strong>Buse</strong> J. The GENNID study. A resource for mapping <strong>the</strong> genes that cause NIDDM.<br />
Diabetes Care 19:864-72, 1996.<br />
72. Fleming GF, Vokes EE, <strong>Buse</strong> JB, Mick R, Dushay J, Levitan D, Dolan ME. Peripheral<br />
blood mononuclear cell dihydropyrimidine dehydrogenase activity in volunteers with and<br />
without diabetes mellitus. Cancer Chemo<strong>the</strong>r Pharmacol 37:569-73, 1996.<br />
73. Burant CF, Flink S, DePaoli AM, Chen J, Lee WS, Hediger MA, <strong>Buse</strong> JB, Chang EB. Small<br />
intestine hexose transport in experimental diabetes. Increased transporter mRNA and protein<br />
expression in enterocytes. J Clin Invest 93:578-85, 1994.<br />
74. Olson AL, Liu ML, Moye-Rowley WS, <strong>Buse</strong> JB, Bell GI, Pessin JE. Hormonal/metabolic<br />
regulation <strong>of</strong> <strong>the</strong> human GLUT4/muscle-fat facilitative glucose transporter gene in transgenic<br />
mice. J Biol Chem 268:9839-46, 1993.<br />
75. Herold KC, Nagamatsu S, <strong>Buse</strong> JB, Kulsakdinun P, Steiner DF. Inhibition <strong>of</strong> glucosestimulated<br />
insulin release from bTC3 cells and rodent islets by an analog <strong>of</strong> FK-506.<br />
Transplantation 55:186-92, 1993.<br />
76. <strong>Buse</strong> JB, Yasuda K, Lay TP, Seo TS, Olson AL, Pessin JE, Karam JH, Seino S, Bell GI.<br />
Human GLUT4/muscle-fat glucose-transporter gene. Characterization and genetic variation.<br />
Diabetes 41:1436-45, 1992.<br />
77. Liu ML, Olson AL, Moye-Rowley WS, <strong>Buse</strong> JB, Bell GI, Pessin JE. Expression and<br />
regulation <strong>of</strong> <strong>the</strong> human GLUT4/muscle-fat facilitative glucose transporter gene in transgenic<br />
mice. J Biol Chem 267:11673-6, 1992.<br />
78. Davidson NO, Hausman AM, Ifkovits C, <strong>Buse</strong> JB, Gould GW, Burant CF, Bell GI. Human<br />
intestinal glucose transporter expression and localization <strong>of</strong> GLUT5. Am J Physiol (Cell<br />
Physiol) 31:C795-800, 1992.
<strong>Buse</strong>, Curriculum Vitae p. 11 <strong>of</strong> 29 Updated: August 2008<br />
79. Choi WH, O'Rahilly S, <strong>Buse</strong> J, Rees A, Morgan R, Flier JS, Moller DE. Molecular scanning<br />
<strong>of</strong> <strong>the</strong> insulin-responsive glucose transporter (GLUT4) gene in NIDDM subjects. Diabetes<br />
40:1712-8, 1991.<br />
80. Kusari J, Verma US, <strong>Buse</strong> JB, Henry RR, Olefsky JM. Analysis <strong>of</strong> <strong>the</strong> gene sequences <strong>of</strong> <strong>the</strong><br />
insulin receptor and <strong>the</strong> insulin-sensitive glucose transporter (GLUT-4 ) in patients with<br />
common-type non-insulin-dependent diabetes mellitus. J Clin Invest 88:1323-30, 1991.<br />
81. Muraoka A, Sakura H, Kim K, Kishimoto M, Akanuma Y, <strong>Buse</strong> JB, Yasuda K, Seino S, Bell<br />
GI, Yazaki Y, Kasuga M, Kadowaki T. Polymorphism in exon 4a <strong>of</strong> <strong>the</strong> human<br />
GLUT4/muscle-fat facilitative glucose transporter gene detected by SSCP. Nucleic Acids<br />
Research 19:4313, 1991.<br />
82. Chang EB, Bookstein C, Vaandrager A, DeJonge HR, <strong>Buse</strong> J, Musch MW. Cystic fibrosis<br />
transmembrane regulator mRNA expression relative to ion-nutrient transport in<br />
spontaneously differentiating human intestinal CaCo-2 epi<strong>the</strong>lial cells. J Laboratory and<br />
Clinical Med 118:377-81, 1991.<br />
83. Fukumoto H, Kayano T, <strong>Buse</strong> JB, Edwards Y, Pilch PF, Bell GI, Seino S. Cloning and<br />
characterization <strong>of</strong> <strong>the</strong> major insulin-responsive glucose transporter expressed in human<br />
skeletal muscle and o<strong>the</strong>r insulin-responsive tissues. J Biol Chem 246:7776-9, 1989.<br />
84. Bhatia E, <strong>Buse</strong> JB, Jackson RA. T-cell antigen receptor alpha chain polymorphism in<br />
insulin-dependent diabetes. J Autoimmunity 1:389-97, 1988.<br />
85. Hattori M, <strong>Buse</strong> JB, Jackson RA, Glimcher L, Dorf ME, Minami M, Makino S, Moriwaki K,<br />
Kuzuya H, Imura H, Strauss WM, Seidman JG, Eisenbarth GS. The NOD mouse: recessive<br />
diabetogenic gene in <strong>the</strong> major histocompatibility complex. Science 231:733-5, 1986.<br />
86. <strong>Buse</strong> JB, Rifai-Haddad R, Lees S, Taniguchi H, Chaplin D, Milford EM, Seidman JG,<br />
Eisenbarth GS, Jackson RA. Major histocompatibility complex restriction fragment length<br />
polymorphisms define three diabetogenic haplotypes in BB and BBN rats. J Exp Med<br />
162:444-58, 1985.<br />
87. <strong>Buse</strong> JB, Chaplin DD, Ben-Nun A, Klein KA, Eisenbarth GS, Seidman JG, Jackson RA.<br />
Class I, II and III major histocompatibility complex gene polymorphisms in BB rats.<br />
Diabetologia 22:77-9, 1984.<br />
88. <strong>Buse</strong> JB, Ben-Nun A, Klein KA, Eisenbarth GS, Seidman JG, Jackson RA. Specific class II<br />
gene polymorphism in BB rats. Diabetes 33:700-3, 1984.<br />
89. Jackson RA, <strong>Buse</strong> JB, Rifai R, Pelletier D, Milford EL, Carpenter CB, Eisenbarth GS,<br />
Williams RM. Two genes required for diabetes in BB rats. Evidence from cyclical<br />
intercrosses and backcrosses. J Exp Med 159:1629-36, 1984.<br />
90. Jackson R, Kadison P, <strong>Buse</strong> J, Rassi N, Jegasothy B, Eisenbarth GS. Lymphocyte<br />
abnormalities in <strong>the</strong> BB rat. Metabolism 32 (Suppl. 1):83-6, 1983.<br />
91. Chao J, <strong>Buse</strong> J, Shimamoto K, Margolius H.S. Kallikrein-induced uterine contraction<br />
independent <strong>of</strong> kinin formation. Proc Natl Acad Sci USA 78:6154-7, 1981.<br />
O<strong>the</strong>r peer reviewed papers:<br />
1. <strong>Buse</strong> JB, Caprio S, Cefalu WT, Ceriello A, Del Prato S, Inzucchi SE, McLaughlin S, Phillips<br />
GL 2nd, Robertson RP, Rubino F, Kahn R, Kirkman MS. How do we define cure <strong>of</strong><br />
diabetes? Diabetes Care 32:2133-5, 2009.<br />
2. International Expert Committee. International Expert Committee report on <strong>the</strong> role <strong>of</strong> <strong>the</strong><br />
A1C assay in <strong>the</strong> diagnosis <strong>of</strong> diabetes. Diabetes Care. 2009;32:1327-34.
<strong>Buse</strong>, Curriculum Vitae p. 12 <strong>of</strong> 29 Updated: August 2008<br />
3. Nathan DM, <strong>Buse</strong> JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B for<br />
<strong>the</strong> American Diabetes Association and <strong>the</strong> European Association for Study <strong>of</strong> Diabetes.<br />
Medical management <strong>of</strong> hyperglycemia in type 2 diabetes: a consensus algorithm for <strong>the</strong><br />
initiation and adjustment <strong>of</strong> <strong>the</strong>rapy: a consensus statement <strong>of</strong> <strong>the</strong> American Diabetes<br />
Association and <strong>the</strong> European Association for <strong>the</strong> Study <strong>of</strong> Diabetes. Diabetes Care. 2009;<br />
32:193-203. (Simultaneously published as Diabetologia. 2009; 52:17-30. )<br />
4. Skyler JS, Bergenstal R, Bonow RO, <strong>Buse</strong> J, Deedwania P, Gale EA, Howard BV, Kirkman<br />
MS, Kosiborod M, Reaven P, Sherwin RS; American Diabetes Association; American<br />
College <strong>of</strong> Cardiology Foundation; American Heart Association. Intensive glycemic control<br />
and <strong>the</strong> prevention <strong>of</strong> cardiovascular events: implications <strong>of</strong> <strong>the</strong> ACCORD, ADVANCE, and<br />
VA diabetes trials: a position statement <strong>of</strong> <strong>the</strong> American Diabetes Association and a<br />
scientific statement <strong>of</strong> <strong>the</strong> American College <strong>of</strong> Cardiology Foundation and <strong>the</strong> American<br />
Heart Association. Diabetes Care. 2009; 32:187-92. (Simultaneously published as<br />
Circulation 2009; 119:351-7 and J Am Coll Cardiol. 2009; 53:298-304.)<br />
5. <strong>Buse</strong> JB. Are prescribing patterns <strong>of</strong> antidiabetic medications influenced by fears <strong>of</strong><br />
litigation? Nat Clin Pract Endocrinol Metab. 2008; 4:440-1.<br />
6. Hicks J, Muller M, Panteghini M, <strong>John</strong> G, Deeb L, <strong>Buse</strong> J, Nathan DM, Kahn R, Ferrannini<br />
E, Heine R, Silink M, Mbanya JC for <strong>the</strong> American Diabetes Association, European<br />
Association for <strong>the</strong> Study <strong>of</strong> Diabetes, International Federation <strong>of</strong> Clinical Chemistry and<br />
Laboratory <strong>Medicine</strong>, and <strong>the</strong> International Diabetes Federation. Consensus statement on <strong>the</strong><br />
worldwide standardization <strong>of</strong> <strong>the</strong> hemoglobin A1C measurement. Simultaneously published:<br />
Diabetes Care 30:2399-2400, 2007, Clinical Chemistry 53:1562-1564, 2007<br />
7. Dungan K, Chapman J, Braithwaite SS, <strong>Buse</strong> J. Glucose measurement: confounding issues<br />
in setting targets for inpatient management. Diabetes Care 30: 403-409, 2007.<br />
8. <strong>Buse</strong> JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC,<br />
Grundy S, Nesto RW, Pignone MP, Plutzky J, Porte D, Redberg R, Stitzel KF, Stone NJ.<br />
Primary prevention <strong>of</strong> cardiovascular diseases in people with diabetes: a joint statement and<br />
recommendations from <strong>the</strong> American Diabetes Association and <strong>the</strong> American Heart<br />
Association. Diabetes Care 30:167-172, 2007 and Circulation 115:114-26, 2007.<br />
9. Nathan DM, <strong>Buse</strong> JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B.<br />
Management <strong>of</strong> hyperglycemia in type 2 diabetes mellitus: A consensus algorithm for <strong>the</strong><br />
initiation and adjustment <strong>of</strong> <strong>the</strong>rapy. Simultaneously published: Diabetes Care 29:1963-<br />
1972, 2006 and Diabetologia 49:1711-21, 2006.<br />
10. <strong>Buse</strong> JB, Rosenstock J. Prevention <strong>of</strong> cardiovascular outcomes in type 2 diabetes mellitus:<br />
Trials on <strong>the</strong> horizon. Cardiology Clinics 23:211-220, 2005.<br />
11. Kahn R, <strong>Buse</strong> J, Ferrannini E, Stern M, American Diabetes Association, European<br />
Association for <strong>the</strong> Study <strong>of</strong> Diabetes. The metabolic syndrome: time for a critical appraisal:<br />
joint statement from <strong>the</strong> American Diabetes Association and <strong>the</strong> European Association for<br />
<strong>the</strong> Study <strong>of</strong> Diabetes. Simultaneously publishedL Diabetes Care 28:2289-304, 2005 and<br />
Diabetologia 48:1684-99, 2005.<br />
12. Al-Arouj M, Bouguerra R, <strong>Buse</strong> J, Hafez S, Hassanein M, Ibrahim MA, Ismail-Beigi F, El-<br />
Kebbi I, Khatib O, Kishawi S, Al-Madani A, Mishal AA, Al-Maskari M, Nakhi AB, Al-<br />
Rubeanm K. Recommendations for management <strong>of</strong> diabetes during Ramadan. Diabetes Care<br />
28:2305-11, 2005.<br />
13. Hirsch IB, Bergenstal RM, Parkin CG, Wright, Jr., E, <strong>Buse</strong> JB. A real-world approach to<br />
insulin <strong>the</strong>rapy in primary care practice. Clinical Diabetes 23:78-86, 2005.
<strong>Buse</strong>, Curriculum Vitae p. 13 <strong>of</strong> 29 Updated: August 2008<br />
14. Dungan K and <strong>Buse</strong> JB. Glucagon-like peptide 1-based <strong>the</strong>rapies for type 2 diabetes: A focus<br />
on exenatide. Clinical Diabetes 23:56-62, 2005.<br />
15. <strong>Buse</strong> JB, Rosenstock J. Prevention <strong>of</strong> cardiovascular outcomes in type 2 diabetes mellitus:<br />
trials on <strong>the</strong> horizon. Endocrinol Metab Clin North Am. 34:221-35, 2005.<br />
16. <strong>Buse</strong> J, Tan MH, Prince MJ, Erickson PP. The effects <strong>of</strong> oral antihyperglycemic medications<br />
on serum lipid pr<strong>of</strong>iles in patients with type 2 diabetes. Diabetes, Obesity and Metabolism<br />
6:133-56, 2004.<br />
17. ACCORD Study Group. The ACCORD Trial: A Multidisciplinary Approach to Control<br />
Cardiovascular Risk in Type 2 Diabetes Mellitus. Practical Diabetology 23 (4): 6-11, 2004.<br />
18. Peters Harmel AL, Kendall DM, <strong>Buse</strong> JB, Boyle PJ, Marchetti A, Lau H. Impact <strong>of</strong><br />
adjunctive thiazolidinedione <strong>the</strong>rapy on blood lipid levels and glycemic control in patients<br />
with type 2 diabetes. Current Medical Research and Opinion 20:215-223, 2004.<br />
19. Barrett E, Blonde L, Clement S, Davis J, Devlin J, Kane J, Klein S, Torrey W, Allison D,<br />
Bergman R, <strong>Buse</strong> J, Cavazzoni P, Fiedorek F, Ganguli R, Greenspan A, Kendall D, Leonge<br />
R, Loebel A, Lustman P, Meltzer H, Newcomer J, Racoosin J, Roth B, Sernyak M, Thakore<br />
J, Wirshing D, Wirshing W for <strong>the</strong> American Diabetes Association, <strong>the</strong> American Psychiatric<br />
Association, <strong>the</strong> American Association <strong>of</strong> Clinical Endocrinologists and <strong>the</strong> North American<br />
Association for <strong>the</strong> Study <strong>of</strong> Obesity. Consensus development conference on antipsychotic<br />
drugs and obesity and diabetes. Obesity Research 12:362-368, 2004.<br />
20. <strong>Buse</strong> J. Statin treatment in diabetes mellitus. Clinical Diabetes 21:168-172, 2003.<br />
21. <strong>Buse</strong> J. Evolution in <strong>the</strong> American Diabetes Association Standards <strong>of</strong> Care<br />
Clinical Diabetes 21:24-26, 2003.<br />
22. Genuth S, Alberti KG, Bennett P, <strong>Buse</strong> J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC,<br />
Lebovitz H, Lernmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stern<br />
M, Tuomilehto J, Zimmet P; Expert Committee on <strong>the</strong> Diagnosis and Classification <strong>of</strong><br />
Diabetes Mellitus. Follow-up report on <strong>the</strong> diagnosis <strong>of</strong> diabetes mellitus. Diabetes Care<br />
26:3160-7, 2003.<br />
23. <strong>Buse</strong> JB. Should postprandial glucose be routinely measured and treated to a particular<br />
target? No! Diabetes Care 26:1615-8, 2003.<br />
24. <strong>Buse</strong> JB. Lipid changes associated with diabetes <strong>the</strong>rapy. Practical Diabetology 22(1):24-9,<br />
2003.<br />
25. <strong>Buse</strong> JB. Patient Information: Protect your heart, protect your life. Clinical Diabetes, 21:<br />
173, 2003.<br />
26. <strong>Buse</strong> JB. Practical Pointers: Statin treatment in diabetes mellitus. Clinical Diabetes, 21:<br />
168-72, 2003.<br />
27. Kendall DM, Sobel BE, Coulston AM, Peters Harmel AL, McLean BK, Peragallo-Dittko V,<br />
<strong>Buse</strong> JB, Fonseca VA, Hill JO, Nesto RW, Sunyer FX; Partners Against Insulin Resistance<br />
Advisory Panel. The insulin resistance syndrome and coronary artery disease. Coronary<br />
Artery Disease 14:335-48, 2003.<br />
28. <strong>Buse</strong> JB, Freeman JL, Edelman SV, Jovanovic L, McGill JB. Serum 1,5-anhydroglucitol<br />
(GlycoMark ): a short-term glycemic marker. Diabetes Technology and Therapeutics 5:355-<br />
63, 2003.<br />
29. Sherwin RS, Anderson RM, <strong>Buse</strong> JB, Chin MH, Eddy D, Fradkin J, Ganiats TG, Ginsberg H,<br />
Kahn R, Nwankwo R, Rewers M, Schlessinger L, Stern M, Vinicor F, Zinman B. The<br />
prevention or delay <strong>of</strong> type 2 diabetes. Diabetes Care 26 (Suppl 1):s62-9, 2003.
<strong>Buse</strong>, Curriculum Vitae p. 14 <strong>of</strong> 29 Updated: August 2008<br />
30. American Diabetes Association. Consensus statement: <strong>the</strong> prevention or delay <strong>of</strong> type 2<br />
diabetes. Diabetes Care 25:742-749, 2002.<br />
31. <strong>Buse</strong> JB, Weyer C, Maggs DG. Amylin replacement with pramlintide in type 1 and type 2<br />
diabetes: A physiological approach to overcome barriers with insulin <strong>the</strong>rapy. Clinical<br />
Diabetes 20:137-144, 2002.<br />
32. <strong>Buse</strong> JB. Metabolic side effects <strong>of</strong> antipsychotics: focus on hyperglycemia and diabetes.<br />
Journal <strong>of</strong> Clinical Psychiatry 63(supplement 4): 37-41, 2002.<br />
33. <strong>Buse</strong>, JB. Diabetes tactics: Aggressive treatment <strong>of</strong> type 2 diabetes. Current Practice (The<br />
<strong>of</strong>ficial publication <strong>of</strong> <strong>the</strong> Council for <strong>the</strong> Advancement <strong>of</strong> Diabetes Research and Education)<br />
1(2):4-6, 2002.<br />
34. <strong>Buse</strong> JB. Insulin analogues. Current Opinion in Endocrinology & Diabetes 8:95-100, 2001.<br />
35. American Diabetes Association. Consensus statement: postprandial blood glucose. Diabetes<br />
Care 24:775-778, 2001.<br />
36. <strong>Buse</strong> JB. Progressive use <strong>of</strong> medical <strong>the</strong>rapies in type 2 diabetes. Diabetes Spectrum 13(4):<br />
211-220, 2000.<br />
37. <strong>Buse</strong> JB. Combining insulin and oral agents. American Journal <strong>of</strong> <strong>Medicine</strong> 108<br />
(Supplement 6a): 23-32, 2000.<br />
38. <strong>Buse</strong>, JB. Thiazolidinediones in <strong>the</strong> treatment <strong>of</strong> type 2 diabetes: a clinician’s perspective.<br />
American Journal <strong>of</strong> Managed Care 6(suppl 13):s710-7, 2000.<br />
39. <strong>Buse</strong>, JB. Pioglitazone in <strong>the</strong> treatment <strong>of</strong> type 2 diabetes mellitus: U.S. clinical experience.<br />
Experimental and Clinical Endocrinology & Diabetes (suppl 2) 108: 250-255, 2000.<br />
40. <strong>Buse</strong>, JB. The use <strong>of</strong> insulin alone and in combination with oral agents in type 2 diabetes.<br />
Primary Care Clinics in Office Practice 26: 931-50, 1999.<br />
41. American Diabetes Association. Consensus development conference on diabetic foot wound<br />
care. Simultaneously published Diabetes Care 22:1354-60, 1999 and Journal <strong>of</strong> <strong>the</strong><br />
American Podiatric Medical Association 89:475-483, 1999.<br />
42. <strong>Buse</strong> JB. Overview <strong>of</strong> current <strong>the</strong>rapeutic options in type 2 diabetes. Rationale for<br />
combining oral agents with insulin <strong>the</strong>rapy. Diabetes Care 22(suppl. 3): c65-70, 1999.<br />
43. <strong>Buse</strong>, JB. Management <strong>of</strong> glycemia in type 2 diabetes. Clinical Cornerstone. 1(3):39-57,<br />
1998.<br />
44. <strong>Buse</strong> JB and Hroscikoski M. The case for a role <strong>of</strong> postprandial glucose monitoring in<br />
diabetes management. Journal <strong>of</strong> Family Practice 47(suppl.):s29-s36, 1998.<br />
45. Sobel R, Meyer G, <strong>Buse</strong> JB. Brittle diabetes lessons for intensive insulin management.<br />
Practical Diabetology 13:12-22, 1994.<br />
46. Bell GI, Kayano T, <strong>Buse</strong> JB, Burant CF, Takeda J, Lin D, Fukumoto H, Seino S. Molecular<br />
biology <strong>of</strong> mammalian glucose transporters. Diabetes Care 13:198-208, 1990.<br />
47. <strong>Buse</strong> JB and Eisenbarth GS. Autoimmune endocrine disease. Vitamins and Hormones<br />
42:253-314, 1985.<br />
48. <strong>Buse</strong> JB and Eisenbarth GS. Monoclonal antibodies in endocrine immunodiagnosis.<br />
Clinical Chemistry News 9:19-21, 1982.<br />
49. <strong>Buse</strong> JB, Rowley RH, Eisenbarth GS. Disordered cellular immunity in type I diabetes <strong>of</strong><br />
man and <strong>the</strong> BB rat. Survey <strong>of</strong> Immunological Research 1:339-51, 1982.<br />
Editorials and Letters:<br />
1. <strong>Buse</strong> JB. Can we become victims <strong>of</strong> our own success? Diabetes Care 32:2140-1, 2009.
<strong>Buse</strong>, Curriculum Vitae p. 15 <strong>of</strong> 29 Updated: August 2008<br />
2. <strong>Buse</strong> JB. A dead heat: target normal glucose levels in <strong>the</strong> intensive care unit-but with<br />
caution. Diabetologia. 51(6):909-10, 2008.<br />
3. Carek PJ, <strong>Buse</strong> JB; Association <strong>of</strong> Family <strong>Medicine</strong> Residency Directors. Frontline:<br />
diabetes--supplementing education and quality improvement in family medicine residency<br />
training. Ann Fam Med. 2008;6:88-9.<br />
4. <strong>Buse</strong> JB, Lundberg GD. Can <strong>the</strong> American Diabetes Association have an impact on<br />
preventing and treating <strong>the</strong> diabetes epidemic in 2007-2008? An interview with <strong>the</strong> incoming<br />
president. MedGenMed. 2007;9:9.<br />
5. <strong>Buse</strong> J, Pignone M. Response to Dr. Nicolucci and co-workers. Diabetes Care 30:E---,<br />
2007. DOI: 10.2337/dc07-0463.<br />
6. Kahn R, <strong>Buse</strong> J, Ferrannini E, Stern M. The metabolic syndrome: Time for a critical<br />
appraisal: Joint statement from <strong>the</strong> American Diabetes Association and <strong>the</strong> European<br />
Association for <strong>the</strong> Study <strong>of</strong> Diabetes - Response to Citrome et al., Giugliano and Esposito,<br />
Cheta, and Psaty et al. Diabetes Care 29:177-178, 2006.<br />
7. Kahn R, <strong>Buse</strong> J, Ferrannini E, Stern M. The metabolic syndrome. Lancet 366:1921-2, 2005.<br />
8. <strong>Buse</strong> JB. Glitazones and heart failure: critical appraisal for <strong>the</strong> clinician. Circulation.<br />
108(8):e57, 2003.<br />
9. <strong>Buse</strong> J. Evolution in <strong>the</strong> ADA Standards <strong>of</strong> Care. Clinical Diabetes 21: 24-6, 2003.<br />
10. <strong>Buse</strong> JB. Should postprandial glucose be routinely measured and treated to a particular<br />
target? Connecting <strong>the</strong> two sides <strong>of</strong> <strong>the</strong> debate. Diabetes Care. 26(9):2700-1, 2003.<br />
11. <strong>Buse</strong> J and Raftery L. What we think and what we know. Diabetes Care 25:1876-8, 2002.<br />
12. <strong>Buse</strong> JB. Diabetic genetics: a complex picture. Consultant 42:452, 2002.<br />
13. <strong>Buse</strong> JB. High insulin levels: target for treatment? Consultant 41: 502,5, 2001.<br />
14. <strong>Buse</strong> J. Insulin glargine (HOE901): first responsibilities: understanding <strong>the</strong> data and ensuring<br />
safety. Diabetes Care. 23:576-8, 2000.<br />
Manuscripts in press, submitted or in final preparation<br />
1. <strong>Buse</strong> JB. Standards <strong>of</strong> Care. In: The Uncomplicated Guide to Diabetes Complications, 3rd<br />
edition. Pfeifer M, ed. American Diabetes Association, in press. 8 pages.<br />
2. <strong>Buse</strong> JB, Ratner RE, Stonehouse AH, Kendall DM. Exenatide: a review <strong>of</strong> clinical data.<br />
Diabetes Metabolism Research Reviews. Resubmitted. 2008. 32 pages.<br />
3. American Diabetes Association (J <strong>Buse</strong>, contributing editor). Medical Management <strong>of</strong> Type<br />
2 Diabetes, 6 th Edition (Charles F. Burant, Ed.) American Diabetes Association. In press,<br />
2008.<br />
4. Matt Petersen, <strong>John</strong> <strong>Buse</strong>, Eric Boerwinkle, and <strong>the</strong> American Diabetes Association<br />
GENNID Study Group. GENNID: A shareable repository <strong>of</strong> genetic material for <strong>the</strong> study<br />
<strong>of</strong> type 2 diabetes. Resubmitted. 2006<br />
5. Allison DB, Cavazzoni P, Beasley CM, Berg PH, Mukhopadhyay N, Mallinckrodt C, Baker<br />
RW, Holcombe JH, Taylor CC, Breier A, <strong>Buse</strong> JB. Effects <strong>of</strong> antipsychotics on random<br />
blood glucose concentrations in patients with schizophrenia participating in double-blind,<br />
randomized, controlled clinical trials. Submitted. 2005. 40 pages.<br />
6. <strong>Buse</strong> JB, Gause D, Boyko WL, Ryu S, Dirani R, Crystal-Peters J, Doyle JJ. Onychomycosis<br />
and secondary infections in patients with diabetes. Submitted. 2004. 31 pages.<br />
7. Jago R, Bassin S, McMurray R, Pyle L for <strong>the</strong> Studies to Treat Or Prevent Pediatric Type 2<br />
Diabetes Prevention Study Group. How much activity can be obtained from modified middle<br />
physical education lessons – pilot study results. Submitted. 19 pages.
<strong>Buse</strong>, Curriculum Vitae p. 16 <strong>of</strong> 29 Updated: August 2008<br />
8. Jago R, McMurray RG, Bassin S, Pyle L, Bruecker S, Jakicic JM, Moe E, Murray T, Volpe<br />
SL for <strong>the</strong> STOPP-T2D Prevention Study Group. Modyfying US middle school PE: Piloting<br />
strategies to increase physical activity. Submitted. 2008 24 pages.<br />
9. McMurray RG, Jago R, Bassin SL, Coombs LP, Rubin DA, Harrell JS, Thompson D, <strong>Buse</strong><br />
JB for <strong>the</strong> Studies to Treat Or Prevent Pediatric Type 2 Diabetes Prevention Study Group.<br />
The relationship between insulin resistance and measures <strong>of</strong> adiposity <strong>of</strong> ethnically diverse<br />
adolescents. Final draft, 23 pages.<br />
Monograph Publications:<br />
1. <strong>Buse</strong> JB, Henry RR. A practical approach to <strong>the</strong> management <strong>of</strong> type 2 diabetes in <strong>the</strong><br />
context <strong>of</strong> cardiovascular risk. Pri-Med in Practice. Primed, Boston, MA, 2006. 2 pages<br />
2. Hirsch IB, Blonde L, <strong>Buse</strong> J, Close K, Edelman SV, Peters A, Valentine V, Wysham C, Garg<br />
S. Consensus Development Conference on Pramlintide in <strong>the</strong> Management <strong>of</strong> Type 1 and<br />
Type 2 Diabetes. The Diabetes Education Group, Lakeville, CT, 2006. 16 pages.<br />
3. Management <strong>of</strong> Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic State in Adults.<br />
(JB <strong>Buse</strong>, M Menke, TS Sisca, editorial review board). Scherer Clinical Communication,<br />
2005. 24 pages.<br />
4. Anonymous. Diabetic Ketoacidosis in <strong>the</strong> Adult Patient. (<strong>John</strong> B. <strong>Buse</strong>, Thomas S. Sisca,<br />
Marsha Menke, editorial review board). HealthAnswers, Inc. 2002<br />
5. <strong>Buse</strong> JB. Recent findings: five epidemiological studies who comparable rates <strong>of</strong> diabetes<br />
among antipsychotic agents. In: Clinical Perspectives in Psychiatry. Medical Education<br />
Network, New York, 2002<br />
6. <strong>Buse</strong> JB. Metabolic Side Effects: Focus on Hyperglycemia and Diabetes. In: JCP Visuals.<br />
Physicians Postgraduate Press, Inc., 2002 (2 pages).<br />
7. <strong>Buse</strong> JB. Diabetes Treatment: Focus on Postprandial Glucose. In: Postprandial<br />
Hyperglycemia in Type Diabetes. Postgraduate Institute for <strong>Medicine</strong>, 2002 (3 pages).<br />
8. Anonymous. The Basics <strong>of</strong> Continuous Subcutaneous Insulin Infusion Therapy. Editorial<br />
Review Board (<strong>John</strong> B. <strong>Buse</strong>, Thomas S. Sisca, Jane Young). HealthAnswers, Inc. 2002.<br />
9. <strong>Buse</strong> JB. New treatment strategies for type 2 diabetes: Where are we now and where are we<br />
going?. In: Current Diabetes Care: The evolving role in <strong>the</strong> pharmacist and emerging<br />
treatment strategies. BioScience Communications, New York, NY, 2001. (7 pages)<br />
10. Anonymous. American Pharmaceutical Association New Product Bulletin. Lantus (insulin<br />
glargine). Advisory Board (Chair: <strong>John</strong> R. White; Members: Janelle F. Bagsall, <strong>John</strong> B.<br />
<strong>Buse</strong>, Betsy A. Carlisle). American Pharmaceutical Association, Washington, DC, 2000.<br />
11. Bruntlett E and <strong>Buse</strong> JB. The role <strong>of</strong> medical nutrition <strong>the</strong>rapy in type 2 diabetes. In:<br />
Mediguide to Diabetes (Whitehouse FW, ed.). Lawrence DellaCorte Publications, Inc, New<br />
York, NY. 4(5):1-6, 1998.<br />
12. Kahn C, <strong>Buse</strong> JB, Lebovitz HE, Nadeau D. Postprandial hyperglycemia: Implications for<br />
NIDDM. Boston. Pharmedica Press, Killingworth, CT. December, 1997. (12 pages)<br />
13. Golden TD, <strong>Buse</strong> JB, Lebovitz HE. Postprandial hyperglycemia: Implications for NIDDM.<br />
Atlanta. Pharmedica Press, Killingworth, CT. December, 1997. (12 pages)<br />
14. Baron AD, <strong>Buse</strong> JB, Lebovitz HE. Postprandial hyperglycemia: Implications for NIDDM.<br />
Chicago. Pharmedica Press, Killingworth, CT. December, 1997. (12 pages)<br />
15. Davidson JA, Lebovitz HE, <strong>Buse</strong> JB, Svec F. Postprandial hyperglycemia: Implications for<br />
NIDDM. Dallas. Pharmedica Press, Killingworth, CT. December, 1997. (12 pages)
<strong>Buse</strong>, Curriculum Vitae p. 17 <strong>of</strong> 29 Updated: August 2008<br />
16. Edelman SV, <strong>Buse</strong> JB, Lebovitz HE. Postprandial hyperglycemia: Implications for<br />
NIDDM. San Fransisco. Pharmedica Press, Killingworth, CT. December, 1997. (12 pages)<br />
17. <strong>Buse</strong> JB. Myths Regarding Diabetes Care and Coronary Disease. Lipid Nurse Task Force<br />
Newsletter, Milwaukee, WI. 1999, 4 pages.<br />
18. <strong>Buse</strong> JB. Advances in Diabetes Treatment - Implications for Lipid Management. Lipid<br />
Nurse Task Force Newsletter, Milwaukee, WI. 1999, 4 pages.<br />
19. <strong>Buse</strong> JB. Insulin Resistance: Role in <strong>the</strong> Clinical Management <strong>of</strong> Diabetes. Pharmedica<br />
Communications, Killingworth, CT. 1999, 24 pages.<br />
20. <strong>Buse</strong> JB and Bruntlett EQ. Making Nutrition Work in <strong>the</strong> Management <strong>of</strong> Type 2 Diabetes:<br />
A Guide for Patients. Bayer Corporation, West Haven, CT. 1999, 13 pages.<br />
21. <strong>Buse</strong> JB and Bruntlett EQ. Making Nutrition Work in <strong>the</strong> Management <strong>of</strong> Type 2 Diabetes:<br />
A Guide for Diabetes Care Providers. Bayer Corporation, West Haven, CT. 1999. 38 pages.<br />
22. <strong>Buse</strong> J. Diabetic Emergencies. Acute Glycemic Control. In: Patterns <strong>of</strong> Care: Guidelines for<br />
Diabetes Care. Patterns <strong>of</strong> Care Task Force. The North Carolina Diabetes Advisory Council.<br />
Raleigh, NC. 1999, 11 pages.<br />
23. <strong>Buse</strong> J and Yarborough P. Diabetes Management. Long Term Glycemic Control. In:<br />
Patterns <strong>of</strong> Care: Guidelines for Diabetes Care. Patterns <strong>of</strong> Care Taks Force. The North<br />
Carolina Diabetes Advisory Council. Raleigh, NC. 1999, 11 pages.<br />
24. Berlin C and <strong>Buse</strong> J. Is <strong>the</strong>re a role for cardiovascular risk factor reduction in premenopausal<br />
woman with diabetes? Lipid Nurse Task Force Newsletter, Milwaukee, WI.<br />
1998, 3 pages.<br />
25. <strong>Buse</strong> JB, Edelman SV, Knudson PE. Clinical Case Studies in Diabetes. Pearls and Pitfalls.<br />
A Focus on NIDDM for <strong>the</strong> Specialist. (AD Baron, ed). Clinical Communications,<br />
Greenwich, CT. 1997 (33 pages).<br />
26. <strong>Buse</strong> JB, Edelman SV, Knudson PE. Clinical Case Studies in Diabetes. Pearls and Pitfalls.<br />
A Focus on NIDDM. (AD Baron, ed). Clinical Communications, Greenwich, CT. 1997 (33<br />
pages).<br />
Book reviews:<br />
1. <strong>Buse</strong>, JB. Review <strong>of</strong> Ralph DeFronzo's Current Therapy <strong>of</strong> Diabetes Mellitus. Doody's<br />
Review Service (on-line). Available at http://www.doody.com. December 1, 1997.<br />
2. <strong>Buse</strong>, JB. Review <strong>of</strong> Ralph DeFronzo's Current Therapy <strong>of</strong> Diabetes Mellitus. Annals <strong>of</strong><br />
Internal <strong>Medicine</strong>. 128:331-2, 1998.<br />
Online Content:<br />
1. Dungan K and <strong>Buse</strong> J. Amylin and GLP-1-based <strong>the</strong>rapies for <strong>the</strong> treatment <strong>of</strong> diabetes. In:<br />
UpToDate, (Rose, BD, editor). UpToDate, Wellesley, MA, 2005-2007.<br />
2. Perkins DO, Keefe RSE, Citrome L, <strong>Buse</strong>, JB Liffick, LF. CME Circle: Enhancing<br />
Outcomes by Addressing Critical Challenges in <strong>the</strong> Treatment <strong>of</strong> Schizophrenia. Medscape<br />
Psychiatry and Mental Health. Posted: 9/26/03. Available at:<br />
http://www.medscape.com/viewprogram/2632.<br />
3. Zinman B, Malik RA, Gardner TW, Taylor R, <strong>Buse</strong> JB. CME Circle: Pathways Leading to<br />
Diabetic Microvascular Complications and <strong>the</strong> Latest Clinical Therapies. Medscape Diabetes<br />
and Endocrinology. Posted: 9/22/03. Available at:<br />
http://www.medscape.com/viewprogram/2636.
<strong>Buse</strong>, Curriculum Vitae p. 18 <strong>of</strong> 29 Updated: August 2008<br />
4. <strong>Buse</strong> JB. Ask <strong>the</strong> Expert: Waiting for a Change in A1C. Medscape Diabetes and<br />
Endocrinology. Posted: 9/9/03. Available at: http://www.medscape.com/viewarticle/460876.<br />
5. <strong>Buse</strong> JB. Clinical Update: Diabetes Management in <strong>the</strong> 21st Century: Multiple Therapeutic<br />
Options for Achieving Glycemic Control. Medscape Diabetes and Endocrinology. Posted:<br />
12/13/2000. Available at http://www.medscape.com/viewprogram/595.<br />
6. <strong>Buse</strong>. JB. Ask <strong>the</strong> Expert: A Case <strong>of</strong> Malingering? Medscape Diabetes and Endocrinology.<br />
Posted:3/14/03. Available at: http://www.medscape.com/viewprogram/595.<br />
7. <strong>Buse</strong> JB. Ask <strong>the</strong> Expert: The Lowest Glucose <strong>of</strong> <strong>the</strong> Day. Medscape Diabetes and<br />
Endocrinology. Posted: 3/11/03. Available at:<br />
http://www.medscape.com/viewarticle/450197.<br />
8. <strong>Buse</strong> JB. Ask <strong>the</strong> Expert: Alpha-glucosidase Inhibitors for Type 1 Diabetes. Medscape<br />
Diabetes and Endocrinology. Posted: 11/13/01. Available at:<br />
http://www.medscape.com/viewarticle/412376.<br />
9. <strong>Buse</strong>, JB. Ask <strong>the</strong> Expert: Rotating Injection Sites. Posted: 10/04/01. Available at:<br />
http://www.medscape.com/viewarticle/412395.<br />
10. <strong>Buse</strong> JB. Ask <strong>the</strong> Expert: Agents Interfering with Home Testing <strong>of</strong> Blood Glucose.<br />
Medscape Diabetes and Endocrinology. Posted: 9/25/01. Available at:<br />
http://www.medscape.com/viewarticle/412368.<br />
11. <strong>Buse</strong> JB. Ask <strong>the</strong> Expert: The Severely Insulin-Resistant Patient with Anti-Insulin<br />
Antibodies. Medscape Diabetes and Endocrinology. Available at:<br />
http://www.medscape.com/viewarticle/412371.<br />
12. <strong>Buse</strong> JB. Ask <strong>the</strong> Expert: Risk <strong>of</strong> Hepatotoxicity with New Thiazolidinediones. Medscape<br />
Diabetes and Endocrinology. Available at: http://www.medscape.com/viewarticle/412413.
<strong>Buse</strong>, Curriculum Vitae p. 19 <strong>of</strong> 29 Updated: August 2008<br />
Teaching Record<br />
Lectures:<br />
Course Co-Director, Management <strong>of</strong> Diabetes Mellitus (MEDI 608, NURS 608, PHCY 608;<br />
2003-present)<br />
Course Director, Biomedical Sciences Selective on Diabetes (Spring, 1997)<br />
Approximately two sessions per year in "The Endocrine System: Mechanisms <strong>of</strong> Disease",<br />
second year course, School <strong>of</strong> <strong>Medicine</strong>.<br />
Approximately one to four per year to graduate students in <strong>the</strong> each <strong>of</strong> <strong>the</strong> following at <strong>UNC</strong>:<br />
School <strong>of</strong> Public Health, <strong>Department</strong> <strong>of</strong> Nutrition<br />
School <strong>of</strong> Nursing<br />
School <strong>of</strong> <strong>Medicine</strong><br />
Approximately four per year to residents, faculty and fellows in <strong>the</strong> <strong>Department</strong> <strong>of</strong> <strong>Medicine</strong><br />
Approximately two to four per year in <strong>the</strong> o<strong>the</strong>r <strong>Department</strong>s within <strong>the</strong> School <strong>of</strong> <strong>Medicine</strong><br />
Clinical Teaching:<br />
One teaching clinic every fourth week with Endocrinology Fellows<br />
Visiting trainees from <strong>the</strong> School <strong>of</strong> Nursing, School <strong>of</strong> Public Health, School <strong>of</strong> Pharmacy,<br />
School <strong>of</strong> Social Work, AHEC Visiting Faculty Program<br />
Continuing Education Lectures:<br />
Sponsored by <strong>UNC</strong>-CH AHEC - Approximately three per year<br />
Sponsored by o<strong>the</strong>r NC AHEC's - Approximately three per year<br />
Sponsored by o<strong>the</strong>r medical schools - Approximately five per year<br />
Sponsored by o<strong>the</strong>r CME providers – Approximately 50-100 per year<br />
Student preceptorship:<br />
Each summer one funded student works in <strong>the</strong> diabetes program; previous students have come<br />
from <strong>the</strong> School <strong>of</strong> Pharmacy, School <strong>of</strong> Public Health, School <strong>of</strong> <strong>Medicine</strong> and <strong>the</strong><br />
undergraduate campus<br />
Attending on Clinical Teaching Services:<br />
General Internal <strong>Medicine</strong> Inpatient Service (1995-1997, 2001-2006)<br />
Endocrine Consult Service (1994-2002; 2008-present)<br />
General <strong>Medicine</strong> Consult Service (2001-2005)<br />
Graduate Student Committees:<br />
Alisa Hughley, PhD; School <strong>of</strong> Public Health<br />
Debra Muio, PhD; <strong>Department</strong> <strong>of</strong> Nutrition<br />
Carmen Samuel-Hodge, PhD; <strong>Department</strong> <strong>of</strong> Nutrition
<strong>Buse</strong>, Curriculum Vitae p. 20 <strong>of</strong> 29 Updated: August 2008<br />
Grants<br />
Current Support:<br />
Protocol#: HC-99-61, NIH/NHLBI PI: G<strong>of</strong>f (<strong>Buse</strong>, Clinical Ctr PI, Study Vice-Chair)<br />
10/1/99-9/31/09 Percent Effort: 25% Annual Direct Cost: $51,939<br />
Title <strong>of</strong> Project: Prevention <strong>of</strong> cardiovascular disease in diabetes mellitus - clinical center<br />
network.<br />
Protocol#: Protocol # U01DK061223, NIH PI: Joanne Harrell, PhD (<strong>Buse</strong>, co-investigator)<br />
09/01/01 - 08/31/08 Percent Effort: 15% Annual Direct Cost:<br />
Physical activity in youth – preventing type 2 diabetes.<br />
Protocol#: DIAD, BMS/Fujisawa PI: Dostou (<strong>Buse</strong> co-investigator)<br />
6/1/01-05/31/09 Percent Effort: 1% Annual Direct Cost: $23,542<br />
Title <strong>of</strong> Project: Detection <strong>of</strong> ischemia in asymptomatic diabetics.<br />
Protocol#: CDJN608B2302, Novartis PI: Dostou (<strong>Buse</strong> co-investigator and Steering Committee)<br />
4/01/02-03/01/10 Percent Effort: 2% Annual Direct Cost: $7,262<br />
Title <strong>of</strong> Project: A multinational, randomized, double-blind, placebo-controlled, forced titration,<br />
2X2 factorial design study <strong>of</strong> efficacy and safety <strong>of</strong> long term administration <strong>of</strong> nateglinide and<br />
valsartan in <strong>the</strong> prevention <strong>of</strong> diabetes and cardiovascular outcomes in subjects with Impaired<br />
glucose tolerance.<br />
Protocol #: A217-1022, Pfizer PI: <strong>Buse</strong><br />
7/01/02-open ended Percent Effort: 6% Annual Direct Cost: $158,641<br />
Title <strong>of</strong> Project: Efficacy and safety <strong>of</strong> EXUBERA (inhaled insulin) compared with<br />
subcutaneous human insulin <strong>the</strong>rapy in adult subjects with type 1 diabetes mellitus.<br />
Protocol: A217-1029, Pfizer PI: <strong>Buse</strong><br />
7/01/02-open ended Percent Effort: 4% Annual Direct Cost: $126,675<br />
Title <strong>of</strong> Project: Efficacy and safety <strong>of</strong> EXUBERA (inhaled insulin) compared with<br />
subcutaneous human insulin <strong>the</strong>rapy in adult subjects with type 2 diabetes mellitus: A two year<br />
outpatient, open label, parallel group comparative trial.<br />
Protocol# CLAF237A, Novartis PI: <strong>Buse</strong><br />
4/1/04-continuing Percent Effort: 1% Annual Direct Cost: $25,641<br />
Title <strong>of</strong> Project: A multicenter, randomized, double-blind study to compare <strong>the</strong> effects <strong>of</strong> 24<br />
weeks treatment with LAF237 (50 mg bid or 100 mg qd) to placebo in drug naïve patients with<br />
type 2 diabetes.<br />
Protocol #NN2211-1574, Novo Nordisk Pharmaceuticals, Inc. PI: <strong>Buse</strong><br />
5/26/2006-5/26/2009 Percent Effort: 1% Annual Direct Cost: $50,605<br />
Title <strong>of</strong> Project: Liraglutide effect and action in diabetes (LEAD-4): Effect on glycemic control<br />
<strong>of</strong> liraglutide in combination with rosiglitazone plus metformin versus rosiglitazone plus<br />
metformin in type 2 diabetes (a 26-week, double-blind, parallel trial to investigate safety and<br />
efficacy.<br />
Protocol #137-150, Amylin and Eli Lilly PI: <strong>Buse</strong>
<strong>Buse</strong>, Curriculum Vitae p. 21 <strong>of</strong> 29 Updated: August 2008<br />
5/1/2006-4/31/2007 Percent Effort: 3% Annual Direct Cost: $101,819<br />
Title <strong>of</strong> Project: Exenatide LAR: A randomized, open-label, multicenter study to examine <strong>the</strong><br />
effects <strong>of</strong> exenatide long-acting release on glucose control (HbA1C) and safety in subjects with<br />
type 2 diabetes managed with diet modification and exercise and/or oral antidiabetic<br />
medications.<br />
Protocol # INT-201, Transition Therapeutics PI: <strong>Buse</strong><br />
3/1/2006-2/28/2007 Percent <strong>of</strong> Effort 1% Annual Direct Cost 75,388<br />
Title <strong>of</strong> Project: A phase I/II randomized, double-blind, controlled clinical trial to evaluate <strong>the</strong><br />
safety, tolerability, pharmacokinetic pr<strong>of</strong>ile and effects <strong>of</strong> repeated subcutaneous doses <strong>of</strong> E1 in<br />
combination with G1 in patients with type 1 diabetes.<br />
Protocol # P12/722-S3/A3, Medtronic-MiniMed PI : <strong>Buse</strong><br />
03/01/2007-03/31/2009 Percent Effort 2% Annual Direct Cost: 88,824<br />
Title <strong>of</strong> Project: A Prospective, Randomized, Two-arm Study to Compare <strong>the</strong> Efficacy <strong>of</strong> <strong>the</strong><br />
MiniMed Paradigm REAL-Time System Versus Multiple Daily Injection(MDI) in Subject with<br />
Type 1 Diabetes Mellitus -Naïve to Insulin Pump Therapy (STAR 3) P12/722/S3/A3<br />
Protocol # NN2211-1797, Novo Nordisk PI: <strong>Buse</strong><br />
8/22/07-8/31/08 Percent Effort: 1% Annual Direct Cost: 37,531<br />
Title <strong>of</strong> Project: Liraglutide Effect and Action in Diabetes (LEAD-6) Effect on glycemic control<br />
<strong>of</strong> liragultide or exenatide added to metformin, sulfonylurea or a combination <strong>of</strong> both in subject<br />
with type 2 diabetes<br />
Protocol # BCB106, Amylin PI: <strong>Buse</strong><br />
02/14/08-02/13/2011 Percent Effort: 2% Annual Direct Cost: 10,389<br />
Title <strong>of</strong> Project: A randomized, double-blind, parallel-group, multicenter study to compare <strong>the</strong><br />
glycemic effects, safety, and tolerability <strong>of</strong> exenatide long-acting release to those <strong>of</strong> sitagliptin<br />
and pioglitazone in subjects with type 2 diabetes mellitus treated with metformin<br />
Protocol # American Academy <strong>of</strong> Family Practice PI: Edwin Fisher PhD<br />
Percent Effort 10% Annual Direct Cost:<br />
Title <strong>of</strong> project: Peers for Progress.<br />
The purpose <strong>of</strong> <strong>the</strong> study is to demonstrate <strong>the</strong> effectiveness <strong>of</strong> peer counseling to improve<br />
diabetes care and develop materials to facilitate peer counseling in <strong>the</strong> future.<br />
Protocol # 1 R01 ES015326-01A2 PI: Miroslav Styblo<br />
08/07/08-05/31/2010 Percent Effort 4% Annual Direct Cost: 87,015<br />
Title <strong>of</strong> Project: Environmental arsenic and diabetes mellitus<br />
The purpose <strong>of</strong> <strong>the</strong> study is to evaluate arsenic as a cause <strong>of</strong> diabetes through in vitro, animal and<br />
epidemiological studies.
<strong>Buse</strong>, Curriculum Vitae p. 22 <strong>of</strong> 29 Updated: August 2008<br />
Prior Grant Support (<strong>UNC</strong> only):<br />
2005 PI, Clinical Evaluation <strong>of</strong> <strong>the</strong> Safety and Feasibility <strong>of</strong> <strong>the</strong> Investigational BD Continuous<br />
Glucose Monitoring Sensor (Becton-Dickinson Research Laboratories)<br />
PI, Multicenter, double-blind, randomized, placebo controlled, dose ranging phase 2<br />
study to investigate efficacy, safety, tolerability and pharmacokinetics <strong>of</strong> <strong>the</strong> DPP-IV<br />
inhibitor RO0730699 in patients with type 2 diabetes, who are treated with a stable<br />
dose <strong>of</strong> metformin. (H<strong>of</strong>fman-LaRoche)<br />
2004 PI, A Study <strong>of</strong> <strong>the</strong> Safety and Effectiveness <strong>of</strong> <strong>the</strong> DexCom Continuous Glucose Monitor<br />
in Patients with Type 1 Diabetes Mellitus (DexCom)<br />
PI, A Randomized, Double-blind, Placebo Controlled, Rising Dose, Multicenter Study to<br />
Evaluate <strong>the</strong> Safety and Efficacy <strong>of</strong> 90 Days <strong>of</strong> 300 or 600 mg Daily Subcutaneous<br />
Injections <strong>of</strong> INGAP peptide in Type 1 Diabetes Mellitus Patients. (Quintiles)<br />
PI, A Randomized, Double-blind, Placebo Controlled, Rising Dose, Multicenter Study to<br />
Evaluate <strong>the</strong> Safety and Efficacy <strong>of</strong> 90 Days <strong>of</strong> 300 or 600 mg Daily Subcutaneous<br />
Injections on INGAP peptide in Type 2 Diabetes Mellitus Patients. (Quintiles)<br />
PI, Anhydroglucitol (1,5-AG) and Postprandial Hyperglycemia as Measured by<br />
Continuous Glucose Monitoring System (CGMS) in Inadequately Controlled Patients<br />
with Diabetes (Tomen, Japan)<br />
PI, A study <strong>of</strong> <strong>the</strong> safety and effectiveness <strong>of</strong> <strong>the</strong> DexCom Continuous Glucose Monitor<br />
in patients with type 1 diabetes mellitus. (Dexcom)<br />
2003 PI, An open-Label Study to Examine <strong>the</strong> Long Term effect on Glucose Control and Safety<br />
and Tolerability <strong>of</strong> AC2993 Given Two Times a Day to Subjects with Type 2<br />
Diabetes Mellitus (Amylin)<br />
Co-investigator, A phase 3 randomized, double blind, placebo controlled multicenter trail<br />
to evaluate <strong>the</strong> safety and efficacy <strong>of</strong> BMS 298585 in combination with metformin<br />
<strong>the</strong>rapy in subjects with type 2 diabetes who have inadequate glycemic control on<br />
metformin <strong>the</strong>rapy alone. (Bristol Myers Squibb)<br />
2002 PI, Retrospective Study for <strong>the</strong> Collection <strong>of</strong> DNA from Patients Previously Enrolled in<br />
Study 1014 (Pfizer)<br />
Co-investigator, 12-week, Multinational, Mulitcenter, Controlled Open 1:1:1<br />
Randomized, Parallel Clinical Trial to Assess Noninferiorty Between Pre-and Post -<br />
Meal Administration <strong>of</strong> HMR 1964 and Pre-Meal Regular Human Insulin in Subjects<br />
with Type 1 Diabetes Mellitus Receiving Insulin Glargine as <strong>the</strong> Basal Insulin<br />
Therapy (Aventis)<br />
PI, A Phase 3 Randomized Triple Blind Parallel Group Long Term Placebo Controlled<br />
Multicenter Study to Examine <strong>the</strong> Effect on Glucose Control <strong>of</strong> AC2993 Given two<br />
times a day in subjects with Type 2 Diabetes Mellitus Treated with Metformin Alone<br />
(Amylin)<br />
PI, A Phase 3 Randomized Triple Blind Parallel Group Long Term Placebo Controlled<br />
Multicenter Study to Examine <strong>the</strong> Effect on Glucose Control <strong>of</strong> AC2993 Given two<br />
times a day in subjects with Type 2 Diabetes Mellitus Treated with Sulfonylurea<br />
Alone (Amylin)<br />
Co-investigator, A 26-week multinational, mulitcenter, open clinical extension trial to<br />
assess 1 year safety <strong>of</strong> HMR 1964 compared with regular insulin injected<br />
subcutaneously in subjects with type 2 diabetes mellitus also using NPH Insulin and<br />
previously participating in study HMR 1964-3002 (Aventis)
<strong>Buse</strong>, Curriculum Vitae p. 23 <strong>of</strong> 29 Updated: August 2008<br />
PI, A Phase 3 Randomized Triple Blind Parallel Group Long Term Placebo Controlled<br />
Multicenter Study to Examine <strong>the</strong> Effect on Glucose Control <strong>of</strong> AC2993 Given two<br />
times a day in subjects with Type 2 Diabetes Mellitus Treated with Metformin and<br />
Sulfonylurea (Amylin)<br />
PI, A Randomized Triple-Blind Placebo-Controlled Multicenter Study to Investigate <strong>the</strong><br />
safety <strong>of</strong> Pramlintide Treatment Employing Pramlintide Dose-Titration Followed by<br />
Insulin Dose Optimization in Subjects with Type 1 Diabetes (Amylin)<br />
Co-investigator, The An<strong>the</strong>m Study; Advicor in <strong>the</strong> Treatment <strong>of</strong> Diabetic Patients with<br />
Dyslipidemia Using Thiazolidinedione (KOS)<br />
PI, A Randomized, Double-Blind, Comparator-Controlled Study <strong>of</strong> Pioglitazone HCI vs<br />
Glyburide in <strong>the</strong> Treatment <strong>of</strong> Subjects with Type 2 (Non-Insulin Dependent)<br />
Diabetes Mellitus and Mild Cardiac Disease (NYHA I) (Takeda)<br />
2001 Co-investigator, A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter<br />
Study to Examine <strong>the</strong> Effect <strong>of</strong> Glucose Control <strong>of</strong> AC 2993 (0.08/ug/kg) Given<br />
Threes Times a Day Versus Twice a Day for 29 Days in Subjects with Type 2<br />
Diabetes Mellitus Treated with Sulfonylureas and/or Metformin (Amylin)<br />
PI, Clinical Effectiveness <strong>of</strong> <strong>the</strong> Diasensor 2000 Noninvasive Glucose Meter used in a<br />
De-Centralized Environment (Biocontrol)<br />
PI, Single dose and 34-Day Tolerance Study <strong>of</strong> INGAP Peptide in Insulin Deficient<br />
Patients (GMP)<br />
2000 Co-investigator, Cardiovascular Health in Children and Youth (NIH, NINR)<br />
PI, A Randomized, Multi-Center, Placebo Controlled, Double-Blind, Parallel Group<br />
Clinical Trial to Assess <strong>the</strong> Effect <strong>of</strong> Three Months Repeated Daily Oral 1200 mg<br />
Doses <strong>of</strong> D-Chiro-Inositol (INS-1), in Combination with Oral Sulfonylureas Control<br />
and Lipid Pr<strong>of</strong>iles in Patients with Type 2 Diabetes. (Insmed)<br />
PI, Pioglitazone Versus Rosiglitazone in Subjects with Type 2 Diabetes Mellitus and<br />
Dyslipidemia. (Lilly)<br />
PI, Safety <strong>of</strong> Pulmonary Insulin in Patients with Type 2 Diabetes (Lilly)<br />
PI, A Long-Term, Double-Blind, Placebo Controlled, Parallel Group Study <strong>of</strong> Zenarestat<br />
(CI-1014) in Diabetic Patients at Risk <strong>of</strong> Foot Ulcer. (Parke-Davis)<br />
PI, A 12-Week, Double-Blind, Placebo-Controlled, Multi-Center Study to Compare <strong>the</strong><br />
Effect <strong>of</strong> Zenerstat (CI-1014) with Enalapril on Microalbuminuria in Diabetes<br />
Patients. (Parke-Davis)<br />
PI, A 12-month, Multi-Center, Open-Label Extension to Protocol 1014-001 to Evaluate<br />
<strong>the</strong> Safety <strong>of</strong> Zenarestat (CI-1014) in <strong>the</strong> Treatment <strong>of</strong> Diabetic Neuropathy. (Parke-<br />
Davis)<br />
PI, A 20-Week, Double-Blind, Randomized, Active-Controlled, Multicenter Study<br />
Comparing Efficacy and Safety <strong>of</strong> Troglitazone Plus Metformin or Rosiglitazone Plus<br />
Metformin to Metformin Plus Placebo in Type 2 Diabetic Patients Not Optimally<br />
Controlled on Metformin. (Parke-Davis)<br />
PI, A Multicenter, Randomized, Double-Blind, Parallel Group, Clinical Evaluation <strong>of</strong><br />
Oral GI262570 Sodium Tablets (2.5mg, 5 mg and 7.5mg) in Combination with<br />
Metformin for 26 Weeks Duration in Subjects with Type 2 Diabetes Mellitus who<br />
Are Inadequately Controlled on a Maximum Dose <strong>of</strong> Metformin. (Glaxo-Wellcome)
<strong>Buse</strong>, Curriculum Vitae p. 24 <strong>of</strong> 29 Updated: August 2008<br />
PI, Target Glycemic Control and <strong>the</strong> Incidence <strong>of</strong> Symptomatic Nocturnal Hypoglycemia<br />
in Insulin Naïve Subjects with Type 2 Diabetes on Oral Hypoglycemic Agent(s) and<br />
Treated with Insulin Glargine or NPH Human Insulin. (Hoescht Marion Roussel)<br />
PI, A Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Evaluate<br />
<strong>the</strong> Role <strong>of</strong> <strong>the</strong> Addition <strong>of</strong> Amaryl to NIDDM Patients not Responding to Maximum<br />
Dose Metformin and Thiazolininedione (Aventis)<br />
Co-investigator, A 24 Week, Multicenter, Double-Blind, Randomized, Parallel Group<br />
Fixed Dose Study to Prospectively Evaluate <strong>the</strong> Safety, Efficacy and Tolerability <strong>of</strong><br />
Nateglinide plus Rosiglitazone Combination Therapy in Patients with Type 2<br />
Diabetes Mellitus Inadequately Controlled with Prior Rosiglitazone Mono<strong>the</strong>rapy and<br />
Diet (Novartis)<br />
PI, Pioglitazone Versus Rosiglitazone in Subjects with Type 2 Diabetes Mellitus And<br />
Dyslipidemia (Lilly)<br />
1999 PI, Randomized, Double-Blind, Placebo Controlled, Dose-Response Trial <strong>of</strong>. Akesis Pro<br />
Health Pak (proprietary dietary supplement for diabetes and pre-diabetes) in Type 2<br />
Diabetes (Akesis)<br />
PI, A Double-Blind, Placebo-Controlled, Multi-Center, Crossover Study to Investigate<br />
<strong>the</strong> Efficacy and Safety <strong>of</strong> <strong>the</strong> Glucagon Receptor Antagonist BAY27-9955 in <strong>the</strong><br />
Treatment <strong>of</strong> Patients With Type 2 Diabetes Mellitus Inadequately Controlled With<br />
Insulin Therapy (Bayer)<br />
PI, A 24-Week, Double-Blind Study <strong>of</strong> Troglitazone (Rezulin) in Combination with<br />
Sulfonylurea or in Combination with Sulfonylurea Plus Metformin in Type 2<br />
Diabetes Patients Inadequately Controlled on Sulfonylurea. (Parke-Davis)<br />
PI, A 26-Week, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to<br />
Evaluate <strong>the</strong> Safety and Efficacy <strong>of</strong> Rosiglitazone Administered Twice a Day in<br />
Combination with a Sulfonylurea and Metformin in Patients With Type 2 Diabetes<br />
Mellitus Inadequately Controlled and Sulfonylurea and Metformin (SmithKline<br />
Beecham)<br />
1998 PI, A 16 Week Multicenter, Controlled, Randomized, Open Label Clinical Trial<br />
Comparing HOE 901 Insulin and NPH Human Insulin in Subjects with Type 1<br />
Diabetes Treated with Lispro (Hoechst Marion Roussel)<br />
PI, A 24-Week, Double Blind Study <strong>of</strong> Troglitazone versus Placebo in Patients with Type<br />
II Diabetes Mellitus Who Require Insulin (Parke-Davis)<br />
PI, Insulin Delivery Using a 3.0mL Disposable Pen Device (Lilly)<br />
PI, A Multicenter Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging<br />
Clinical Evaluation <strong>of</strong> Oral GI262570X as a Mono<strong>the</strong>rapy for 12 Weeks Duration in<br />
Subjects with Type 2 Diabetes Mellitus (Glaxo Wellcome)<br />
PI, A 32 Week, Randomized Controlled Trial Evaluating <strong>the</strong> Efficacy <strong>of</strong> Self Blood<br />
Glucose Monitoring in Patients with Type 2 Diabetes Mellitus (<strong>UNC</strong>/GCRC)<br />
PI, Safety and Efficacy <strong>of</strong> Fixed Combination Metformin/Glyburide Products as First<br />
Line Therapy in Patients with Type 2 Diabetes Mellitus Who Have Inadequate<br />
Glycemic Control with Diet and Exercise (Bristol-Myers Squibb)<br />
PI, A 24 Month, Double-Blind, Randomized, Placebo-Controlled, Fixed-Dose, Parallel-<br />
Group Multicenter Study <strong>of</strong> Zenerestat (CI-1014) in <strong>the</strong> Treatment <strong>of</strong> Diabetic<br />
Neuropathy (Parke-Davis)
<strong>Buse</strong>, Curriculum Vitae p. 25 <strong>of</strong> 29 Updated: August 2008<br />
1997 PI, A Six Month Multicenter, Randomized, Parallel, Open-Label Efficacy and Safety<br />
Study Comparison <strong>of</strong> <strong>the</strong> Human Insulin Analogue X14 and Regular Human Insulin<br />
as Meal Related Insulin in a Multiple Injection Regimen in Subjects with Type II<br />
Diabetes (Novo-Nordisk/BioPharm)<br />
PI, A 28-Week, Multicenter, Controlled, Randomized Open Clinical Trial Comparing<br />
HOE 901 Insulin With NPH Human Insulin in Subjects With. Type I Diabetes<br />
(Hoechst Marion Roussel)<br />
PI, A 28-Week, Multicenter, Controlled, Randomized Open Clinical Trial Comparing<br />
HOE 901 Insulin with NPH Human Insulin in Subjects with Type II Diabetes<br />
(Hoescht Marion Roussel)<br />
PI, A Six Month Multicenter, Randomized, Parallel, Open-Label Efficacy and Safety<br />
Study Comparison <strong>of</strong> <strong>the</strong> Human Insulin Analogue X14 and Regular Human Insulin<br />
as Meal Related Insulin in a Multiple Injection Regimen in Subjects with Type I<br />
Diabetes. (Novo- Nordisk/BioPharm)<br />
PI, A Randomized, Double-Blind, P lacebo Controlled, Six-Month Safety and Efficacy<br />
Trial <strong>of</strong> Voglibose (AO-128) 2mg TID and 3mg BID in Type II Diabetes Patients<br />
(Quintiles/Takeda)<br />
PI, A 4-year, Double-blind, Randomized, Placebo-controlled Study <strong>of</strong> Atorvastatin as<br />
Secondary Prevention <strong>of</strong> CHD in Patients with (Type II) Noninsulin Dependent<br />
Diabetes Mellitus (Parke-Davis, Pfizer)<br />
1996 PI, D-chiro-inositol, Pinitol and Myo-inositol Concentrations in Blood and Urine <strong>of</strong><br />
Individuals with Abnormal Glucose Tolerance (Ross Pharmaceuticals and Abbott<br />
Laboratories)<br />
PI, A Placebo-controlled Safety and Efficacy Study <strong>of</strong> Pimagedine in Patients with Type<br />
II Diabetes Mellitus and Overt Diabetic Nephropathy (Alteon)<br />
Co-Investigator, (SIP #24-W) Improving Diabetic Care for Minority Women (NIH, PI<br />
Dr. T. Keyserling)<br />
1995 PI, A 20-week, Double-blind, Randomized Study <strong>of</strong> Troglitazone in Patients with<br />
NIDDM (Parke-Davis)<br />
PI, P.R.O.T.E.C.T. - PRECOSE (Acarbose Tablets): Resolution <strong>of</strong> Optimum Titration to<br />
Enhance Current Therapies (Bayer)<br />
PI, A 31-week, Double-blind Study <strong>of</strong> Troglitazone (CI-991) Versus Placebo in<br />
Noninsulin-Dependent Diabetes Mellitus (NIDDM) Patients Requiring Insulin<br />
(Parke-Davis)<br />
1994 PI, Pimagedine- Safety and Efficacy in Nephrology <strong>of</strong> Insulin-dependent Diabetes<br />
Mellitus (Alteon)<br />
PI, Genetics <strong>of</strong> Non-insulin Dependent Diabetes (GENNID) Study (American Diabetes<br />
Association)<br />
Co-PI, Affiliate Center, Insulin-dependent Diabetes Prevention Trial (NIH/NIDDK)
<strong>Buse</strong>, Curriculum Vitae p. 26 <strong>of</strong> 29 Updated: August 2008<br />
Pr<strong>of</strong>essional Service<br />
Society Memberships:<br />
American Association <strong>of</strong> Clinical Endocrinologists<br />
1998-present Carolinas Affiliate Board Member<br />
American Diabetes Association<br />
2009 Member, Board <strong>of</strong> Directors<br />
2007-2008 President for <strong>Medicine</strong> and Science<br />
2006-2007 President-Elect<br />
2005-2006 Vice-President<br />
2001-2004 National Board Member<br />
1997-2001 Sou<strong>the</strong>rn Region Board Member<br />
1996 President, North Carolina Affiliate<br />
1994 Nor<strong>the</strong>rn Illinois Board Member<br />
Endocrine Society<br />
Society <strong>of</strong> General Internal <strong>Medicine</strong><br />
Consultant:<br />
Amylin Pharmaceuticals<br />
BD Research Laboratories<br />
Bayhill Therapeutics<br />
Bristol-Myers Squibb<br />
Eli Lilly and Company<br />
GlaxoSmithKline<br />
H<strong>of</strong>fman LaRoche<br />
Intuity<br />
Insulet Corporation<br />
LipoScience<br />
Insulet Corporation<br />
Mannkind<br />
Merck<br />
MicroIslet<br />
Novo Nordisk<br />
San<strong>of</strong>i-Aventis<br />
Wyeth<br />
Editorial appointments:<br />
Diabetes Technology & Therapeutics (Editorial Board, April 2006-present)<br />
International Journal <strong>of</strong> Diabetes & Metabolism (International Advisory<br />
Board, December 2005-present)<br />
Clinical Diabetes (Associate Editor, July 2002-December 2005)<br />
Diabetes Care (Associate Editor, 1998-2001)<br />
Reviewer: American Journal <strong>of</strong> <strong>Medicine</strong><br />
American Journal <strong>of</strong> Physiology<br />
Archives <strong>of</strong> Pathology and Laboratory <strong>Medicine</strong><br />
Diabetes
<strong>Buse</strong>, Curriculum Vitae p. 27 <strong>of</strong> 29 Updated: August 2008<br />
Diabetes Care<br />
Diabetes, Metabolism and Obesity<br />
Diabetic <strong>Medicine</strong><br />
Diabetologia<br />
Gastroenterology<br />
Journal <strong>of</strong> <strong>the</strong> American Medical Association<br />
Journal <strong>of</strong> Cardiopulmonary Rehabilitation<br />
Journal <strong>of</strong> Clinical Endocrinology and Metabolism<br />
Journal <strong>of</strong> Clinical Epidemiology<br />
Journal <strong>of</strong> Clinical Investigation<br />
Journal <strong>of</strong> Nutritional Biochemistry<br />
New England Journal <strong>of</strong> <strong>Medicine</strong><br />
Committees:<br />
University: Member, Leadership Committee, NC Translational and Clinical<br />
Science Institute (2008-present)<br />
Member, Steering Committee, NC Translational and Clinical Science<br />
Institute (2008-present)<br />
Member, Grant Review Panel, NC Translational and Clinical Science<br />
Institute (2008-present)<br />
School <strong>of</strong> <strong>Medicine</strong> Member, Carolina Center for Clinical Trials Advisory Board (2006-<br />
present)<br />
Founder, Diabetes Interest Group (2005-present)<br />
Member, Task Force on Pharmacy and Uncompensated Care (2004)<br />
Member, Pharmacy and Therapeutics Committee (2001-present)<br />
Member, Ambulatory Care Operations Group (2001-present)<br />
Chair, Thurston Arthritis Research Center Director Search Committee<br />
(2001-2003)<br />
Chair, Ophthalmology Chair Search Committee (1999-2000)<br />
Member, <strong>UNC</strong> Clinical Research Advisory Committee (1995-1997)<br />
State Member, Patterns <strong>of</strong> Care Task Force <strong>of</strong> <strong>the</strong> North Carolina Diabetes<br />
Advisory Council, <strong>Department</strong> <strong>of</strong> Environment, Health and<br />
Natural Resources (1995-present)<br />
Regional Member, Board <strong>of</strong> Directors, Carolinas Chapter <strong>of</strong> <strong>the</strong> American<br />
Association <strong>of</strong> Clinical Endocrinologists (1999-present)<br />
National Member, Health Care Pr<strong>of</strong>essional Work Group <strong>of</strong> <strong>the</strong> National<br />
Diabetes Education Program, National Institutes <strong>of</strong> Health (2009present)<br />
Member, Clinical Guidelines Leadership Group for Cardiovascular<br />
Risk Reduction, NHLBI (2009-present)<br />
Member, Diabetes Research Strategic Plan Committee, NIDDK (2008present)<br />
Chair, TrialNet External Advisory Committee, NIDDK (2006-present)<br />
Member, Diabetes Mellitus Interagency Coordinating Committee, NIH<br />
(2006-2008)
<strong>Buse</strong>, Curriculum Vitae p. 28 <strong>of</strong> 29 Updated: August 2008<br />
Member, IOOV Data Safety Monitoring Board, Eli Lilly & Co. (2006present)<br />
Member, BHT-3021 Protocol Data Safety and Monitoring Board,<br />
Bayhill Therapeutics (2006-present)<br />
Member, IRIS (Insulin Resistance Intervention After Stroke) Data<br />
Safety Monitoring Board, NINDS (2004-present)<br />
Member, NASH-CRN (Non-Alcoholic SteatoHepatitis Clinical<br />
Research Network) Data Safety Monitoring Board, NIDDK (2004present)<br />
Chair, STOPP-T2D (Studies to Treat Or Prevent Pediatric Type 2<br />
Diabetes) Prevention Study Publications and Presentations<br />
Committee (2004-present)<br />
Member, Experienced Reviewer Reserve, NIDDK (2003-present)<br />
Member, FREEDOM (Future Revascularization Evaluation in Patients<br />
with Diabetes Mellitus: Optimal Management <strong>of</strong> Multivessel<br />
Disease) Trial Steering Committee, NHLBI (2003-present)<br />
Member, NAVIGATOR US Steering Committee, Novartis (2002present)<br />
Chair, Diabetes Cardiovascular Disease Advisory Committee,<br />
American Diabetes Association (2001-present)<br />
Chair, Archimedes Project Advisory Committee, American Diabetes<br />
Association (2002-present)<br />
Vice-Chair, ACCORD (Action to Control Cardiovascular Risk in<br />
Diabetes) Study, NIH/NHLBI (2000-present)<br />
Co-Director, American Diabetes Association Postgraduate Course<br />
(2003)<br />
Member, National Board, American Diabetes Association (2001-2004)<br />
Co-Chair, American Association <strong>of</strong> Clinical Endocrinologists 2000<br />
Annual Meeting Program Committee (1999-2000)<br />
Chair, Pr<strong>of</strong>essional Practice Committee, American Diabetes<br />
Association (2002-2004)<br />
Member, Pr<strong>of</strong>essional Practice Committee, American Diabetes<br />
Association (1999-2004)<br />
Chair, Data Safety Monitoring Board, CONTROL (Combination Oral<br />
& Nutritional Treatment <strong>of</strong> Late-Onset Diabetes Mellitus ) Trial<br />
(1999-2000)<br />
Member, Scientific and Medical Meetings Oversight Committee,<br />
American Diabetes Association (1997-1999)<br />
Member, Pr<strong>of</strong>essional Education Project Team, American Diabetes<br />
Association (1996-1997)<br />
Member, Medical Science Review Committee, Juvenile Diabetes<br />
Foundation International (1996-1998)<br />
International Member, Steering Committee, NAVIGATOR (Nateglinide And<br />
Valsartan in Impaired Glucose Tolerance Outcomes Research)<br />
Trial (2002-present)
<strong>Buse</strong>, Curriculum Vitae p. 29 <strong>of</strong> 29 Updated: August 2008<br />
Member, Independent Data Monitoring Committee, ORIGIN<br />
(Outcome Reduction with Initial Glargine Intervention) Trial<br />
(2003-present)<br />
O<strong>the</strong>r Administrative Activities:<br />
Executive Associate Dean for Clinical Research, <strong>UNC</strong> School <strong>of</strong> <strong>Medicine</strong> (2008-present)<br />
Chief, Division <strong>of</strong> Endocrinology, <strong>Department</strong> <strong>of</strong> <strong>Medicine</strong>, <strong>UNC</strong> School <strong>of</strong> <strong>Medicine</strong> (2007present)<br />
Chief, Division <strong>of</strong> General <strong>Medicine</strong> and Clinical Epidemiology, <strong>Department</strong> <strong>of</strong> <strong>Medicine</strong>,<br />
<strong>UNC</strong> School <strong>of</strong> <strong>Medicine</strong> (2001-2006)<br />
Clinic Director, Highgate Specialty Centre, <strong>UNC</strong> Hospitals and Clinics (1999-2008)<br />
Director, Endocrinology Clinics, Division <strong>of</strong> Endocrinology, <strong>Department</strong> <strong>of</strong> <strong>Medicine</strong>, <strong>UNC</strong><br />
School <strong>of</strong> <strong>Medicine</strong> (1997-2007)<br />
Director, Diabetes Care Center, Division <strong>of</strong> Endocrinology, <strong>Department</strong> <strong>of</strong> <strong>Medicine</strong>, <strong>UNC</strong><br />
School <strong>of</strong> <strong>Medicine</strong> (1994-present)<br />
Co-Chief, Division <strong>of</strong> Endocrinology, <strong>Department</strong> <strong>of</strong> <strong>Medicine</strong>, <strong>UNC</strong> School <strong>of</strong> <strong>Medicine</strong><br />
(1997-2002)<br />
Patents<br />
<strong>Buse</strong> JB, Moses AC. Methods <strong>of</strong> determining concentrations <strong>of</strong> glucose. US Patent 7,058,437.<br />
Issued June 6, 2006.<br />
<strong>Buse</strong> JB, Moses AC. Small volume in vitro analyte sensor with diffusible or non-leachable<br />
redox mediator. US Patent 6,591,125. Issued July 8, 2003.<br />
The 1,5-Anhydroglucitol (1,5-AG) assay and A1C/1,5-AG assay combination for measuring<br />
blood glucose excursions in general and postprandial hyperglycemia in diabetic patients.<br />
U.S. Patent 11/912,171, pending.